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PAPP-A  Pregnancy-associated plasma protein A
PG  Prostaglandin
PhIGFBP-1 Phosphorylated insulin like growth factor-binding protein-1
PPROM   Preterm premature rupture of membranes
PPV  Positive predictive value
PROM  Premature rupture of membranes
PTD  Preterm delivery
PTL  Preterm labour
THL  National Institute for Health and Welfare
TNF-α  Tumour necrosis factor-alpha
WBC  White blood cell
7ABSTRACT
Preterm delivery (PTD) is a major problem in obstetrics. Its incidence varies between 
5% and 15% of all deliveries, depending on the geographic and demographic features of 
the population. Although many risk factors have been identifi ed, early identifi cation of 
pregnant women who will deliver before term remains an important goal. The main purpose 
of this study was to investigate whether measurement of phosphorylated insulin like 
growth factor-binding protein-1 (phIGFBP-1) and matrix metalloproteinase-8 (MMP-8) in 
cervical and vaginal fl uids in early and mid-pregnancy can be used to identify women at 
high risk of spontaneous PTD, and to determine factors infl uencing phIGFBP-1 and MMP-
8 concentrations in the lower genital tract. In one study the usefulness of rapid cervical 
phIGFBP-1 test in predicting PTD was examined among women with self-reported uterine 
contractions between 22 and 34 weeks of gestation.
 
The studies were carried out at the Maternity Clinic of the Department of Obstetrics and 
Gynecology, University of Helsinki, Finland. Vaginal and cervical swab samples for assay 
of phIGFBP-1 and MMP-8 were collected from 5180 unselected pregnant women in the 
fi rst and second trimesters of pregnancy between April 2005 and December 2006. Data 
on pregnancy and delivery were collected from the hospital records. Concentrations of 
phIGFBP-1 were measured by immunoenzymometric assay and in one study by using a 
rapid strip test. Concentrations of MMP-8 were measured by immunofl uorometric assay. 
A concentration of ≥10 μg/l was used as a cut-off for elevated cervical fl uid phIGFBP-1. 
MMP-8 results were presented as percentiles. The main outcome measure was spontaneous 
PTD.
Median concentrations of phIGFBP-1 were over 10-fold higher in the cervix than in the 
vagina in both trimesters. Overall, 25–34% of the women had elevated cervical fl uid 
phIGFBP-1 in the fi rst trimester, and 20–28% in the second trimester. Nulliparity and 
vaginal bleeding during the current pregnancy were independently associated with elevated 
cervical fl uid phIGFBP-1 levels in both trimesters. Sexual intercourse had no effect on 
cervical fl uid phIGFBP-1 consentrations. MMP-8 was detected in almost all women, and 
the concentrations were 3-fold higher in the cervix than in the vagina. The distribution 
of MMP-8 concentrations in early pregnancy did not differ from that in mid-pregnancy. 
Multiparity, bacterial vaginosis and increased white blood cell counts in vaginal wet mounts 
were associated with increased MMP-8 in both trimesters. Recent sexual intercourse was 
associated with low MMP-8 concentrations in the cervix.
8The rate of spontaneous PTD was 4%. An elevated cervical fl uid phIGFBP-1 level in the 
fi rst trimester was an independent predictor of PTD at < 32 and < 37 weeks’ gestation, 
with odds ratios of 3.0 (95% CI 1.3–7.0) and 1.6 (95% CI 1.2–2.3), respectively. In women 
with uterine contractions between 22 and 34 weeks of gestation, a short cervix, a positive 
phIGFBP-1 strip test result (detection limit 10 μg/l), or a combination of both were 
associated with PTD at ≤ 34 weeks or within 14 days (p < 0.01). Cervical fl uid phIGFBP-1 
< 10 μg/l as well as a negative strip test result had high negative predictive values for PTD 
among asymptomatic and symptomatic women, respectively. 
The overall distribution of MMP-8 concentrations in both trimesters was similar in women 
with term delivery and those with spontaneous PTD. However, elevated (> 90th percentile) 
cervical fl uid MMP-8 concentrations in the fi rst and mid-second trimester were associated 
with subsequent spontaneous PTD initiated by preterm labour (PTL). Decreased MMP-
8 in the second trimester was associated with subsequent premature preterm rupture of 
membranes. 
In conclusion, both markers are present in lower genital tract fl uids, but the concentrations 
are more consistent in the cervix. Although cervical fl uid phIGFBP-1 is not appropriate for 
use in the fi rst and mid-second trimester for routine screening of asymptomatic women for 
PTD, it could play a role alone or in combination with other markers and risk factors, when 
assessing the risk of PTD in selected cases throughout pregnancy. The wide range of MMP-
8 concentrations, and the fact that elevated as well as low concentrations are associated 
with an increased risk of PTD, indicate that cervicovaginal MMP-8 cannot be used for 
prediction of PTD, at least in early and mid-pregnancy. 
9INTRODUCTION
Preterm delivery (PTD) is a multifactorial phenomenon having remarkable medical, 
health economic and human effects. Worldwide its frequency varies from 5.0% to 15.0% 
depending on the population (Slattery and Morrison 2002, Honest et al. 2009). Over half 
of PTDs are spontaneous. The molecular pathways leading to PTD are not suffi ciently 
understood. Worldwide the rate of PTD has increased during the past few decades despite 
efforts to address the problem, and with medical progress. Preterm delivery accounts for 
approximately 75% of all neonatal deaths and one half of children`s long-term neurological 
disability. Although many risk factors have been identifi ed, preterm birth is still diffi cult to 
predict (Romero et al. 2006b, Goldenberg et al. 2008).
Ascending infection, occult or clinical, from the vagina is believed to cause infl ammation 
in the choriodecidual space by activating cells to produce pro-infl ammatory cytokines (IL-
1, IL-8, TNF-α). Cytokines increase the production of prostaglandins (PGs), endo- and 
exotoxins and proteases, which may lead to tissue disruption in the choriodecidual space. 
Tissue disruption results in leakage of chorionic and decidual products into the cervix and 
vagina (Lockwood et al 1999, Goldenberg et al. 2000, Goldenberg et al. 2002). Premature 
preterm rupture of the membranes (PPROM) and/or preterm labour (PTL) may be the fi rst 
symptoms of ascending infection in the choriodecidual space.
During the past few decades many studies have been performed to discover new methods 
for prediction of PTD more effectively and earlier (Goldenberg et al. 2005b, Vogel et al. 
2005, Honest et al. 2009). Most predictive markers are relevant when delivery is going 
to happen shortly (Vogel et al. 2005). However, we need markers to screen the general 
pregnant population as part of antenatal care in order to identify women at high risk of 
subsequent PTD and to focus preventive care on them.
For this study two potential biomarkers were selected: One of these is phosphorylated 
insulin like growth factor-binding protein-1 (phIGFBP-1), a major protein product of the 
decidua, which may leak into the lower genital tract as a result of infl ammation-associated 
tissue disruption (Rutanen 2000). The other is matrix metalloproteinase-8 (MMP-8), 
a human neutrophil collagenase, regulated by pro-infl ammatory mediators (Sorsa et al. 
2006, Van Lint and Libert 2006). Our fi rst aim was to determine the concentrations of 
both markers in cervical and vaginal fl uids, and to investigate factors that may affect the 
concentrations in early and mid-pregnancy. Two studies were conducted to clarify whether 
or not assay of phIGFBP-1 and MMP-8 in samples from asymptomatic women in early and 
mid-pregnancy can be used to predict PTD. In one study, cervical fl uid phIGFBP-1 levels 
and clinical examination in prediction of PTD among symptomatic pregnant women in 
later pregnancy were compared.
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REVIEW OF THE LITERATURE
Preterm delivery
Defi nition
Delivery occurring before 37 completed weeks of pregnancy is considered preterm, 
regardless of birth weight (World Health Organization 1970, Steer 2005, Goldenberg et 
al. 2008). Low birth weight, defi ned as less than 2500g, is often associated with preterm 
delivery (PTD). Although all births before 37 weeks of gestation are defi ned as preterm, most 
problems caused by PTD occur in infants delivered before 34 weeks. It is often convenient 
to divide PTD into subgroups according to gestational age. Extreme prematurity occurs at 
23 weeks to 28 weeks, appearing in about 5% of preterm deliveries, about 15% represent 
severe prematurity at 28–31 weeks, about 20% represent moderate prematurity at 32–33 
weeks and 60–70% represent near or late prematurity at 34–37 weeks (Goldenberg et al. 
2008). There is no global lower limit for PTD, but 22+0 completed weeks of gestation is 
generally accepted, corresponding to an average fetal weight of 500 g (EURO-PERISTAT 
Project 2008, Honest et al. 2009, THL 2010). For an individual newborn delivered at these 
gestational weeks it is very diffi cult to predict the outcome. Parents’ opinions regarding 
invasive intensive care should also be considered (Nuffi eld Council on Bioethics 2007). In 
Finland, intensive care of a preterm infant is started from 23–24 weeks of gestation, with 
some variation between hospitals. Expulsion at less than 22 weeks of gestation is called 
spontaneous abortion or miscarriage and resuscitation should not be started (Nuffi eld 
Council on Bioethics 2007).
Traditionally, determination of gestational age at delivery has been based on estimation of 
the fi rst day of the last menstrual period (Steer 2005). The most accurate modern method is 
via assessment of fetal crown–rump length by vaginal ultrasonography in the fi rst trimester 
(Goldstein and Wolfson 1994, Klebanoff 2007). In Finland, ultrasonographic estimation of 
gestational age is included in routine antenatal care.
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Incidence
The incidence of PTD varies, being an average 5% to 15% of all deliveries depending on 
the geographical and demographical features of the population. About 4% of pregnancies 
result in PTD before 34 weeks of gestation (Honest et al. 2009, Slattery and Morrison 
2002,). Over the past several decades, for reasons that are not fully understood, the PTD 
rate has raised worldwide (Goldenberg and Culhane 2006, Goldenberg et al. 2008, Martin 
et al. 2008, Muglia et al. 2010, Slattery and Morrison 2002). However, in Finland and 
Sweden, the rate of preterm deliveries has stayed more stable than elsewhere (Jakobsson 
et al. 2008, Morken et al. 2008, THL 2010). In Finland the rate of PTD has not increased 
since 1987, being 5.2-5.4% among sigleton pregnancies in recent years (Jakobsson et al. 
2008) and the incidence of PTD infants in Finland at 2008 was 5.7% (THL 2010). Sweden 
has reported even a decrease in PTD rate from 6.3% to 5.6% between1984-2001 (Morken 
et al. 2008). In Denmark the total rate of PTD has increased from 5.3% to 6.1% (1994 to 
2004) and in Norway from 6.0 % to 6.4% (Morken et al. 2008). The rate of PTD has also 
increased in most part of Europe varying from about 5% to 11% (Vogel et al. 2005, EURO-
PERISTAT Project 2008). 
In the United States 13% of infants were born at less than 37 weeks of gestation in 2004-
2008. Two decades earlier the fi gure was 9.4% (Goldenberg and Culhane 2006, Muglia et 
al. 2010, Martin et al. 2008). In Canada the increasing trend is similar being from 6.4 % to 
7.1% (Vogel et al. 2005). During last decades the preterm rates in Oceania have been about 
6.0 % (Tracy et al. 2007). The most impressive increase has been explained with medically 
indicated preterm deliveries. (Slattery and Morrison 2002, Ananth and Vintzileos 2006). 
However, also spontaneous PTD rates have increased (Goldenberg et al. 2008, Muglia et 
al 2010).
Classifi cation
Spontaneous preterm delivery
Classically categorized, spontaneous PTD is preceded by either preterm labour or preterm 
premature rupture of the membranes. Spontaneous PTL is defi ned as labour with regular 
contractions and cervical ripening starting before 37 complete weeks of gestation, with 
intact fetal membranes. PPROM is defi ned as spontaneous rupture of fetal membranes at 
13
least one hour before the onset of contractions prior to 37 weeks of gestation, irrespective of 
whether delivery is vaginal or by Caesarean section. About 40–45% of preterm deliveries 
are preceded by spontaneous PTL and 25–30% follow PPROM (Slattery and Morrison 
2002, Goldenberg et al. 2008). 
PPROM before or at 26 weeks of gestation complicates 0.6–0.7% of pregnancies, and 
has been defi ned as mid-trimester PPROM. The limit of fetal viability has progressively 
declined over the past few decades. Therefore, it is relevant to differentiate PPROM into 
subgroups. Pre-viable PROM occurs before the limit of viability, at less than 23 weeks of 
gestation. Treatments aimed at continuing the pregnancy may lead to extended latency and 
delivery of a potentially viable infant. The earlier that PPROM occurs, the higher the risk of 
fetal pulmonary hypoplasia (van Teeffelen et al. 2010). The risks of perinatal morbidity and 
mortality decrease with advancing gestational age at delivery (Mercer 2003). In a recent 
study infant survival seemed to be signifi cantly lower when the onset of preterm birth was 
PPROM as compared with PTL or iatrogenic delivery (Johanzon et al. 2008).
Iatrogenic preterm delivery
About 30–35% of all preterm deliveries are iatrogenic, i.e. labour is either medically 
induced or the infant is delivered by pre-labour Caesarean section (Goldenberg et al. 2008, 
Honest et al. 2009). Indications for induced PTD are serious maternal or fetal complications 
such as severe pre-eclampsia or intrauterine growth retardation (IUGR) (Goldenberg et al. 
2008).
Health consequences
Preterm delivery, particularly before 34 weeks of gestation, is associated with a signifi cant 
risk of death and adverse health and developmental consequences in the newborn infant. It 
accounts for approximately three-quarters of cases of perinatal mortality and nearly one-
half of cases of long-term neurological morbidity (Goldenberg et al. 2002, Slattery and 
Morrison 2002, Goldenberg et al. 2008). However, improvement in neonatal care in the 
last three decades has led to higher rates of survival of very premature infants. Nowadays 
80% of 500–1000 g newborns are alive at one year of age (Goldenberg et al. 2002,EURO-
PERISTAT Project 2008). Complications of PTD include acute health problems and long-
lasting disabilities such as respiratory, gastrointestinal, immunological, hearing and vision 
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problems and cerebral palsy (CP), as well as long-term motor, cognitive, visual, hearing, 
behavioural, social-emotional, health and growth problems (Hack et al. 2002, Tommiska 
et al. 2007). However, because of better survival of very preterm infants, handicap rates 
have substantially increased (Goldenberg et al. 2002). The risks are greatest at the earliest 
gestational ages (≤ 32 weeks) and in low-birth-weight infants (< 1500 g) (Nuffi eld Council 
on Bioethics 2007, Slattery and Morrison 2002, Goldenberg et al. 2002). However, infants 
born just a few weeks too early are also six times more likely to die in their fi rst week of life 
than full-term infants and three times more likely to die before their fi rst birthday (Behrman 
and Butler 2007, Tomashek et al. 2007). In the long term, children born prematurely have 
increased risks of cardiovascular disease, hypertension and diabetes as adults and possibly 
an increased risk of cancer (Rich-Edwards et al. 1997, Spong 2007). Prematurity-associated 
medical complications also predict future educational and occupational impairments that 
extend into late childhood and beyond (Slattery and Morrison 2002, Lindstrom et al. 2007). 
The emotional impact on a family encountering this problem is enormous. In many cases 
the infant is in hospital for a long time and far from home, and parents suffer considerable 
anxiety, with doubts about the child’s survival and full recovery. 
Economic consequences
The delivery of a preterm infant brings considerable health care costs which are strongly 
gestational age-dependent. The costs are not just those incurred while in the hospital’s 
neonatal intensive care unit. Some health problems that develop at this time can persist 
for years, leading to long-lasting use of healthcare and social services, including special 
education and rehabilitation for those with physical handicaps (Escobar et al. 2006a, 
Escobar et al. 2006b, Honest et al. 2009). Maternal hospitalization before and after delivery 
and an increased number of Caesarean sections also increase costs. 
It was recently estimated that PTD in the United States accounts for 85% of infant medical 
care costs, suggesting major cost savings as a result of prevention of preterm birth (Behrman 
and Butler 2007). Studies in the United Kingdom and Ireland show that the cumulative 
costs of hospital admissions incurred during the fi rst 10 years of life are more than twice 
as high among preterm infants compared with children born at term (Petrou 2005). It has 
been predicted that even higher cost differences will occur at a later age, especially in the 
extremely preterm group. 
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The highest costs per case generally occur in the very preterm and extremely preterm 
groups, but the incremental cost for the large number of infants born between 28 and 32 
weeks is approximately 80% of the cost for infants born at less than 28 weeks (Nuffi eld 
Council on Bioethics 2007).
Risk factors of preterm delivery
PTD is a multifactorial syndrome. Although many risk factors for PTD are well known, 
the cause of this complication remains often unexplained. More than half of all preterm 
deliveries occur in apparently low risk pregnancies with no major risk factor and some 
women are more prone than others (Goldenberg et al. 2008, Romero et al. 2006b). Risks 
factors can be divided into three subgroups: Maternal risk factors, pregnancy history related 
risk factors and those associated with  ongoing pregnancy.
Maternal risk factors
In Finnish studies women with pregnancy outside marriage and not taking part in antenatal 
care are at higher risk for PTD (Raatikainen et al. 2005, Raatikainen et al. 2007). Both 
are often associated with low socioeconomic status, smoking, alcohol or drugs abuse and 
poor nutritional status all independent risk factors of PTD as well (Goldenberg et al. 2008, 
Slattery and Morrison 2002). 
Smoking increases the risk of PTD 2-fold. The risk is highest in the extremely and 
moderately preterm groups. Cigarettes biochemical’s, nicotine and carbon monoxide, 
are powerful vasoconstrictors, and are associated with placental damage and decreased 
uteroplacental blood fl ow. Both pathways lead to fetal growth restriction and induced PTD 
(Jakobsson et al. 2007, Tikkanen et al. 2006). Smoking is also associated with systemic 
host infl ammatory response increasing the risk of PTD (Bermudez et al. 2002). 
Heavy alcohol consumption during pregnancy leads to fetal alcohol syndrome and has 
also been associated with PTD. Further, drugs abuse, such as cocaine and heroin, has been 
associated with PTD in several studies (Bennett 1999, Little et al. 1990, Walton-Moss et 
al. 2009).
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Maternal age younger than 20 years or extremes of maternal age increase rates of PTD 
(Morken et al. 2008, Slattery and Morrison 2002). In a Finnish study, advanced maternal 
age increased the risk of PTD by 2% for each additional year in age (Jakobsson et al. 2007).
Signifi cant independent associations with PTD have been reported for low body mass 
index (BMI) at 20 weeks of gestation (Goldenberg 2003, Neggers and Goldenberg 2003). 
However, bigger problem nowadays is the increased prevalence of overweight and obesity, 
which has increased dramatically in developed countries. Overweight women are more 
likely to develop pre-eclampsia and diabetes, which increase the rate of induced PTD 
(Goldenberg et al. 2008). Being overweight is also associated with PPROM. Persistent 
infl ammation may be an explanation for reported association between PPROM and 
overweight (Nohr et al. 2007, Rosenberg et al. 2005). However, in one study among obese 
women the rate of PTD after spontaneous PTL is lower than among normal weight women 
(Ehrenberg et al. 2009).
Psychological and social stress or depression increase the risk of PTD, whereas physical 
activity is not consistently related to the rate of PTD (Challis and Smith 2001, Goldenberg 
et al. 2008, Wadhwa et al. 2001a). One third of women have depressive symptoms during 
pregnancy and 16 % have clinical depression which both increased the risk of PTD 2-fold 
(Goldenberg et al. 2008). 
Genetic factors seem to play an important role in spontaneous PTD. PTD rates are in the 
range of 16-18% among black women compared with 5-12 % for white women in the 
United States and United Kingdom (Goldenberg et al. 2008, Martin et al 2006, Slattery 
and Morrison 2002). Black women are also three to four times more likely to have a very 
early preterm birth than women from other racial or ethnic groups (Goldenberg et al. 
1996). The lowest rates of PTD exist in East-Asians and Hispanics (Ananth and Vintzileos 
2006, Goldenberg et al. 2008, Romero et al. 2006b, Slattery and Morrison 2002). The 
beginning of PTD also differs by ethnic groups. PTD is most commonly preceded by PTL 
in white women, while PPROM is more frequent among black women (Goldenberg et al. 
1996, Goldenberg et al. 2008). Genetic polymorphisms of individual’s genes may explain 
the greater risk of PTD among black women since environmental factors alone have not 
suffi ciently explained this phenomenon (Holst and Garnier 2008, Warren and Silver 2009). 
Black women born in the United States are more likely to have PTD than black women born 
outside the United States. Those black women who have experience of racial discrimination 
are associated with the higher risk for PTD than other black women (Muglia et al. 2010). 
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In genetic studies women with PTD have higher risk to subsequent PTD (Porter et al. 
1997). There is also a tendency for repeated PTD to occur at the same gestational age as 
the previous pregnancies with the same partner (Li 1999). Woman with a sister who has 
given birth to a preterm infant had an 80% higher risk to have a PTD (Goldenberg et al. 
2008). Studies in twins have noted that genetics may account for about 17-36% of preterm 
deliveries (Holst and Garnier 2008).
Recent investigations have focused on infl ammatory and immune response because of 
the evidence of involvement of infl ammation in pregnancy and parturition (Holst and 
Garnier 2008, Macones et al. 2004, Romero et al. 2004). Genetic differences between 
individuals i. e. gene polymorphisms, can result in variation in production and activity of 
proinfl ammatory proteins, causing inadequate immunologic response to infectious stimuli 
(Holst and Garnier 2008). 
Cervical insuffi ciency, a syndrome with early predominant cervical ripening is strongly 
associated with mid-trimester abortion and PTD. It can be primary cervical disease or 
due to uterine trauma or infection with activation of infl ammatory cytokines (Lidegaard 
1994, Lockwood and Kuczynski 1999, Romero et al. 2006b, Anum et al 2010). It has been 
estimated that infection is present in approximately 50% of women with acute cervical 
insuffi ciency. In addition to infections, cervical insuffi ciency may result from congenital 
hypoplasia or repeated cervical dilatation in connection with termination of pregnancy 
(Romero et al. 200b). One iatrogenic reason for cervical damage may be cervical loop 
electrosurgical excision procedure (LEEP) secondary to premalignant cervical disease 
(Jakobsson et al. 2007, Romero et al. 2006). In a Finnish study history of LEEP is associated 
with an increase in spontaneous PTD 3-fold (Jakobsson et al. 2007). In a more resent study 
this association was not found (Werner et al 2010). The rate of spontaneous PTD is also 
increased among women with uterine anomalies (Rossier et al. 2008). 
Many maternal and fetal genetic and environmental factors may affect the risk of PTD 
independently or interactively. Some gene mutations increase the risk of PTD for one 
woman, but not for another. This fact has led to the hypothesis that gene mutations 
require the presence of certain environmental stimuli, such as infection or stress, to have 
clinical signifi cance. For example, pregnant women with their fetuses who are genetically 
programmed to produce high levels of proinfl ammatory mediators would be more likely 
than those producing low concentrations, to exceed the threshold necessary to initiate 
PTL in response to environmental factors (Holst and Garnier 2008, Romero et al. 2004). 
On the other hand, genital tract immune hyporesponsiveness with low concentrations of 
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infl ammatory cytokines are more likely to subsequently develop clinical chorionamnionis 
than those with high levels of cytokines (Simhan et al. 2003).
Pregnancy history related risk factors
About 50 % of all PTD occur primiparous women (Morken et al. 2008, Jakobsson et al. 
2007). However, history of previous PTD is actually the strongest single risk factor. It 
has been reported that risk of PTD ranges from 15% to more than 50 %, depending on 
the number of previous preterm deliveries. For each previous term delivery the risk of a 
subsequent PTD decreases (Goldenberg and Rouse 1998, Goldenberg et al. 2008, Kramer 
2003, Mercer et al. 1999). 
There is also an increased risk of PTD in pregnancies arising in close proximity to previous 
delivery. After adjustment for confounding factors, an interpregnancy interval of less than 6 
months confers greater than 2-fold risk of PTD. A short interval decreases the opportunity to 
replenish the essential maternal nutrient stores which pregnancy consumes and to resolute 
the infl ammatory status with the previous pregnancy (Conde-Agudelo et al. 2006, Smith 
et al. 2003). 
In some studies the induced abortions increase the risk of PTD due to cervical damage 
during termination of pregnancy but the data are contradictory (Ancel et al. 2004, Henriet 
and Kaminski 2001, Thorp et al. 2003). In a recent Finnish study, previous induced abortion 
was not an independent risk factor for PTD (Raatikainen et al. 2006). 
Pregnancy associated risk factors
Multiple gestations, accounting for only 2-3% of pregnancies carry a substantial risk of 
PTD, and result in 12-27% of all preterm deliveries. Over the past decades there was 
a great increase in the incidence of multiple deliveries, largely as a result of the use of 
assisted conception technologies (Goldenberg and Culhane 2006, Goldenberg et al. 2008). 
The marked shift from double embryo transfer to single embryo transfer which has taken 
place during last decade in Finland and elsewhere has decreased the proportion of multiple 
deliveries. In Finland in 2008, 41.9% of all embryo transfers were performed as single 
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embryo transfer and 90.3 % of infants born after in vitro fertilization (IVF) were singletons 
(THL register 2010). Nearly 50-60 % of twins and nearby all higher order multiple gestations 
are born preterm (Goldenberg and Culhane 2006, Goldenberg et al. 2008). About 40% of 
twins will have spontaneous labour or PPROM before 37 weeks of gestation, with others 
having an indicated PTD because of maternal or fetal disorders (Goldenberg et al. 2008, 
Kramer 2003, Slattery and Morrison 2002). 
In vitro fertilization (IVF) is mainly associated to moderately preterm group (Jakobsson et 
al. 2007). The preterm rate for singleton pregnancies after IVF is approximately 12%, and 
this higher rate is due to various factors, including cervical trauma, disturbed implantation, 
infection, uterine malformation, and associated infertility factors (Poikkeus et al. 2007). For 
twin pregnancies conceived after IVF, there was no difference in the rate of PTD or mean 
gestational age at delivery compared with twins conceived spontaneously (Goldenberg et 
al. 2008, Poikkeus et al. 2007, Steer 2005). 
Infection is the most common single risk factor of PTD. Genital tract infections account 
for about 25-40% of preterm deliveries. However, infection is diffi cult to detect due to 
the limitations of conventional microbial techniques and the diffi culties in obtaining 
appropriate diagnostic samples during pregnancy (Goldenberg et al. 2002, Goldenberg et 
al. 2005a, Romero et al. 2006b, Goldenberg et al. 2008). It is known that the relation 
between infection and PTD is not consistent throughout gestation. Spontaneous preterm 
deliveries that occur before the 34th week of gestation, and particularly before the 30th 
week of gestation, have been strongly associated to intrauterine infection. The earlier the 
preterm birth the stronger the association. Infection is rare in late preterm deliveries (at 
34-36 weeks) (Goldenberg et al. 2000, Goldenberg et al. 2002, Iams 2003, Redline 2004, 
Romero et al. 2006b). 
In women with spontaneous PTL and intact membranes, the most commonly identifi ed 
micro-organisms are Ureaplasma urealyticum, Mycoplasma hominis, Gardnerella 
vaginalis, peptostreptococci, and bacteroides species, all vaginal organisms of relatively 
low virulence. After membranes rupture the most often found microbes in the uterus are 
group B streptococci or Escherichia coli and less commonly Chlamydia trachomatis or 
Neisseria gonorrhoeae (Andrews et al. 2000c, Goldenberg et al. 2002, Goldenberg et al. 
2005a, Romero et al. 2006b). 
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Bacterial vaginosis (BV), a condition characterized by a decrease in number of lactobacilli 
and overgrowth of several anaerobic or facultative bacteria, including Garndenella vaginalis, 
Mycoplasma hominis and Ureaplasma urealyticum, has been shown to be present in up 
to 15-20% of pregnant women. It is asymptomatic in approximately 50% of women and 
can resolve spontaneously. Despite substantial microbial overgrowth, BV is not associated 
with signs of infl ammation (Goldenberg et al. 2000, Hay et al. 1994, Romero et al. 2004). 
However, BV has been shown to increase the risk for spontaneous PTD and PPROM 2- to 
3- fold. (Carey et al. 2003, Flynn et al. 1999, Gibbs 1993, Goepfert and Goldenberg 1996, 
Goldenberg et al. 1996, Hauth et al. 2003, Kekki et al. 1999, Kimberlin and Andrews 
1998, Meis et al. 1995) Also the risk of postpartum endometritis is increased (Goldenberg 
et al. 2000, Kekki et al. 2001). Randomized clinical trials have shown confl icting results 
in screening and treatment of BV to prevent PTD (Guise et al. 2001, Kekki et al. 2001, 
Klebanoff et al. 2003, Leitich et al. 2003, Mac Donald et al 2008, Nygren et al 2008). 
Many other genital infections have been associated with PTD with a great variation. The 
reason for this is that women with genital tract infections usually have other risk factors as 
well (Goldenberg et al. 2005a). Syphilis and gonorrhoea have been associated with PTD 
with a 2-fold (Donders et al. 1993) and trichomoniasis with a 1.3-fold risk (Andrews et al. 
2000c). Chlamydia trachomatis infection has been also associated with 2 to 3-fold risk of 
PTD, (Andrews et al. 2000c, Blas et al. 2007, Cheney and Wray 2008). Still the treatment 
of Chlamydia has not been associated with a decreased frequency of PTD (Andrews et al. 
2006). However, routine screening and treatment for Chlamydia trachomatis is important 
due to high incidence especially among young women. This is a necessary part of prenatal 
care to reduce adverse pregnancy outcomes, post-partum endometritis and to reduce the 
risk of the newborn for conjunctivitis and pneumonitis (Blas et al. 2007, Cheney and Wray 
2008). Vaginal group B streptococcus colonisation is not associated with increased risk of 
PTD, but can cause neonatal sepsis and that is why the antibiotic treatment is indicated in 
cases of PPROM (Goldenberg et al. 2005a).
In addition, any systemic infections, such as asymptomatic bacteriuria, pyelonephfritis, 
appendicitis and pneumonia can trigger uteroplacental response leading to PTL and PTD 
(Goldenberg et al. 2008, Slattery and Morrison 2002). Even periodontitis has been linked 
to PTD (Agueda et al. 2008, Boggess 2005, Offenbacher et al. 1996). Malaria is the most 
widely distributed infectious disease associated with spontaneous PTD. Worldwide, 40% 
of pregnant women are exposed to malaria during pregnancy and annually more than 
200,000 neonatal deaths are due to malaria. Also HIV and tuberculosis infections globally 
predispose women to spontaneous PTD and PPROM (Steer 2005).
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Viral infections, such as cytomegalovirus, parvovirus (B19), varicella, enterovirus, 
Coxsakie virus, Echovirus and hepatis E virus, can transfer the placenta. The viruses 
attract directly the fetal tissues causing fetal diseases and later by disseminated infection 
possible stillbirth but in some cases they also associate to PTD (McClure and Goldenberg 
2009). Herpex simplex viruses do not or very rarely cross the placenta and have not been 
associated with PTD (McClure and Goldenberg 2009). As a whole, it seems unlikely that 
maternal viral infection plays an important part in PTD, but further studies are needed 
(Srinivas et al. 2006).
The history of vaginal bleeding  at any time of pregnancy is associated with PTD and also 
other adverse perinatal outcomes (Harlev et al. 2008, McCormack et al. 2008). Vaginal 
bleeding is a manifestation of decidual damage, but can also be idiopathic (McCormack et al. 
2008, Romero et al. 2006b). The risk factors for vaginal bleeding include maternal cigarette 
smoking and cocaine use, chronic hypertension and pre-eclampsia, maternal trauma, 
and hereditary coagulopathies (Tikkanen et al. 2006). It may be a sign of retroplacental 
haematoma detected by ultrasound examination in the fi rst trimester. In late pregnancy 
vaginal bleeding is associated with placental abruption which is a major obstetrical 
emergency (Romero et al. 2006b). The incidence of placental abruption in Finland is 0. 
42% and it is strongly associated with PTD (Tikkanen et al. 2006). General risk factors for 
placental abruption are maternal smoking, use of alcohol, placenta preavia, pre-eclampsia 
and chorionamnionitis (Oyelese and Ananth 2006, Tikkanen et al. 2006). 
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Pathophysiological pathways leading to preterm delivery
Four different main pathways have been described which may lead to PTD: infection/ 
infl ammation, activation of the maternal fetal hypothalamic-pituitary-adrenal (HPA) axis, 
decidual haemorrhage, and uterine over-distension (Figure 1). Many pathways can be 
involved simultaneously (Slattery and Morrison 2002, Vogel et al. 2005, Romero et al. 
2006b, Goldenberg et al. 2008). 
Figure 1.  Main pathways leading to preterm delivery
Infection and infl ammation
Infection and infl ammation are the most important mechanisms leading to PTD by acting 
on the innate immune system (Goldenberg et al. 2000, Romero et al. 2006b). Infl ammation 
is the response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, 
or irritants, while infection is caused by an exogenous pathogen. Infl ammation, especially 
chronic infl ammation, can be simultaneously destructive and protective (Robbins et al 
2010). Histologically confi rmed bacterial infections within the uterus can occur between 
the maternal tissues and fetal membranes (chorioamnionitis), within the amniotic fl uid 
(amnionitis) or within the umbilical cord or the fetus (funisitis). Infection within the 
placenta (villitis) is rare (Figure 2) (Goldenberg et al. 2000).
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Figure 2.  Potential sites of bacterial infection within the uterus
In most cases micro-organisms invade the uterine cavity by ascending from the vagina 
and cervix. Micro-organisms may also invade the uterus by migration from the abdominal 
cavity through the Fallopian tubes, haematogenously through the placenta, or by needle 
contamination at the time of amniocentesis or chorionic-villus sampling (Figure 3) 
(Goldenberg et al. 2000, Slattery and Morrison 2002, Romero et al. 2004, Goldenberg et 
al. 2008). 
The timing of intrauterine infection is not suffi ciently understood. Microbial colonization 
may precede conception, as is the case in chronic endometritis (Korn et al. 1995), or micro-
organisms may invade the uterus during pregnancy (Romero et al. 2004, Goldenberg et 
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al. 2008). During the fi rst trimester, the placenta and embryo are relatively well isolated 
from infection (Goldenberg et al. 2000, Redline 2004). At 18 to 20 weeks of gestation, the 
gestational sac fuses with the uterine lining and organisms from the decidua parietalis access 
the fetal membranes (Redline 2004, Goldenberg et al. 2008). After the fetal membranes 
seal the uterine cavity, the organisms usually no longer ascend from the vagina to the uterus 
(Goldenberg et al. 2000). However, in cases with PPROM the uterine cavity is exposed to 
vaginal bacterial fl ora even later in pregnancy. 
In most cases, especially in early pregnancy, infection and infl ammation in the uterus are 
asymptomatic. If ascending micro-organisms are not destroyed by the mother’s immune 
system after the expanding membranes have sealed the uterine cavity, the infection may 
lead to infection and infl ammation in the chorion, amnion and fetal membranes, before 
becoming symptomatic. Premature preterm rupture of the membranes and PTL may be the 
fi rst symptoms of infection (Goldenberg et al. 2000, Goldenberg et al. 2008). 
Figure 3.  Potential pathways of microorganisms into the uterus
25
Micro-organisms in the vagina produce enzymes such as proteases and mucinases, which 
allow penetration of the cervical mucus plug, favouring the ascent of bacteria. Cervical 
mucus, containing antimicrobial proteins and peptides such us lysozyme, lactoferrin, defensin 
and immunoglobulins, acts like a mechanical and immunological barrier to ascending 
infection from the vagina (Hein et al. 2001). After penetration of the cervical mucus, micro-
organisms spread into the uterine cavity, the decidua and fetal membranes, the so-called 
choriodecidual space. Choriodecidual cells are activated by micro-organisms to produce 
pro-infl ammatory cytokines, such as interleukins-1 (IL-1α and IL-1β), interleukin-6 and 
8 (IL-6 IL-8) and tumour necrosis factor-α (TNF-α). These cytokines act with exotoxins 
and endotoxins to stimulate prostaglandin synthesis from the arachidonic acid reservoir 
of the fetal membranes (Lockwood et al. 1999, Goldenberg et al. 2000, Goldenberg et 
al. 2002, Romero et al. 2006b). Chorionic infection also directly decreases the activity of 
prostaglandin dehydrogenases, allowing increasing quantities of prostaglandins to reach 
the myometrium, while without infections the prostaglandin dehydrogenases in chorionic 
tissue inactivate prostaglandin production (Goldenberg et al. 2000). Prostaglandins have 
a pivotal role in contractions of the smooth muscle of the uterus and the biophysical 
changes associated with cervical ripening (Lockwood et al. 1999, Goldenberg et al. 2000, 
Goldenberg et al. 2002, Romero et al. 2006b). 
Cytokines also initiate neutrophil chemotaxis, infi ltration and activation, leading to synthesis 
and release of matrix metalloproteinases, causing proteolysis in the extracellular matrix 
(Goldenberg et al. 2002, Romero et al. 2006b). While prostaglandins stimulate uterine 
contractions, matrix metalloproteinases attack the chorioamniotic membranes by weakening 
them, leading to rupture of the fetal membranes. In addition, matrix metalloproteinases 
cause tissue disruption in the choriodecidual space and facilitate separation of the chorion 
from the decidual layer in the lower uterine segment as well as ripening of the cervix by 
remodelling the collagen fi bres (Lockwood et al. 1991, Rath et al. 1998, Weiss et al. 2007). 
Tissue disruption in the lower segment of the uterus due to either uterine contractions 
or infection-induced proteolysis, may cause leakage of choriodecidual products, such as 
insulin-like growth factor-binding protein -1 and fetal fi bronectin, into the cervix and 
vagina, where they become detectable (Figure 4) (Lockwood et al. 1991, Rutanen 2000).  
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Figure 4. Ascending infection during early and late pregnancy
When infection reaches the fetus, an increase in both fetal hypothalamic and placental 
production of corticotrophin-releasing hormone causes an increase in fetal corticotrophin 
secretion leading to increasing fetal adrenal production of cortisol. The increased cortisol 
secretion in turn increases the production of prostaglandins, leading to myometrial 
contractions (Yoon et al. 1998, Goldenberg et al. 2000, Goldenberg et al. 2008). The 
pathways leading from choriodecidual infection to PTD are shown in Figure 5. 
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Figure 5.  Potential pathways from choriodecidual bacterial colonization to PTD
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Systemic infection may activate an infl ammatory process that triggers an uteroplacental 
response leading to PTD (Goldenberg et al. 2005a). Micro-organisms serve as a source 
of endotoxins which increase local infl ammatory mediators, including prostaglandins and 
cytokines. This damages host infl ammatory and immune responses, leading to an increase 
of systemic infl ammatory mediators that invade the bloodstream and organs including the 
placenta and uterus (Boggess 2005, Goldenberg et al. 2005a, Goldenberg et al. 2008).
Activation of the maternal-fetal hypothalamic-pituitary-adrenal 
axis
Stress, psychological, social or physical, is one of the main independent risk factors leading 
to PTD, accounting for about 30% of cases. This pathway is typically associated with PTL 
after 32–34 weeks (Iams 2003).
Maternal stress may activate the maternal- fetal hypothalamic-pituitary-adrenal axis system, 
the neuroendocrine stress response, leading to increased concentrations of corticotrophin-
releasing hormone (CHR) (Campbell et al. 1987, Hobel et al. 1999, Wadhwa et al. 2001b). 
CRH mediates pituitary adrenocorticotrophin (ACTH) secretion through maternal and fetal 
pathways, increasing maternal and fetal adrenal cortisol secretion. Cortisol contributes to 
the increased production of prostaglandins by fetal membranes and the decidua through 
the up-regulation of PG synthase and the down-regulation of PG dehydrogenase enzymes 
(Challis and Smith 2001). Prostaglandins cause contractions and bring about cervical 
ripening and they sensitize the myometrium to oxytocin (Campbell et al. 1987).
Decidual haemorrhage
The pathway of PTD by way of decidual haemorrhage, which can occur at any time, 
involves about 20% of preterm births, especially those related to PPROM (Iams 2003). 
Vaginal bleeding caused by decidual haemorrhage or placental abruption is associated 
with a 3- to 4-fold increased risk of subsequent PTD, with damage to the uterine spiral 
arteries (Romero et al. 2006b , Goldenberg et al. 2008). Maternal vascular lesions lead to 
uteroplacental ischaemia. This can manifest as visible or occult vaginal bleeding at any 
time of pregnancy. The precise mechanism leading to onset of PTD with uteroplacental 
ischaemia is not known, but it is thought to be closely related to thrombin generation. 
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Thrombin stimulates coagulation and clot formation, leading to tissue disruption in the 
choriodecidual space (Elovitz et al. 2001, Romero et al. 2006b).
Uterine over-distension
Intra-amniotic pressure remains relatively constant throughout gestation despite the 
growth of the fetus and placenta. It is the result of progressive myometrial relaxation due 
to the effects of progesterone and endogenous myometrial relaxants such as nitric oxide. 
Premature delivery may be triggered by mechanical stretching of the myometrium caused 
by an increase in uterine size that exceeds the ability of the uterus to compensate. Uterine 
over-distension is caused by multi-fetal pregnancy, overload of amniotic fl uid (AF), so-
called polyhydramnion, or uterine anomaly (Iams 2003, Romero et al. 2006b). Stretching 
of the fetal membranes caused by uterine over-distension triggers the increased production 
of cytokines and prostaglandins, and activates oxytocin receptors, leading to an increase in 
myometrial contractility (Romero et al. 2006b).
Prediction of preterm delivery
Rationale
Accurate prediction of PTD among asymptomatic pregnant women and those with 
threatened PTL might offer an opportunity to target more intensive antenatal surveillance 
and prophylactic measures to those most likely to benefi t from primary, secondary or 
tertiary prevention. Primary prevention is prevention of the onset of spontaneous PTD in 
asymptomatic women by cessation of smoking and/or alcohol use, by maintaining a healthy 
genitourinary tract and periodontal status or by administration of maternal progestational 
agents by injection, or use of cervical cerclage in special cases with previous PTD (Vogel et 
al. 2005, Iams et al. 2008, Holst et al. 2009). Secondary prevention involves steps that can 
be taken to attenuate, stop or reverse the progress of spontaneous PTL in its early stages, 
before advanced cervical dilatation by using tocolytic agents. Tertiary prevention means 
measures aimed at preventing neonatal complications associated with prematurity by using 
antenatal corticosteroids to accelerate fetal lung maturity. 
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Predictive markers, in addition to known risk factors, can be specifi c fi ndings in physical 
examination, such as short cervical length in ultrasonographic examination, or the presence 
of a particular substance in body fl uids (Goldenberg et al. 2005b, Vogel et al. 2005, Holst 
et al. 2009). The markers can be used among asymptomatic and symptomatic women. 
Thus, prediction of PTD is useful among asymptomatic women to prevent PTD, and in 
symptomatic women to delay threatened delivery (Holst et al. 2009).
It is likely that in the majority of cases PTD refl ects a long-standing process dating back 
to the fi rst trimester. Therefore, it would be of clinical importance if this condition could 
be predicted before it becomes manifest clinically, as spontaneous PTL or PPROM (Iams 
2003, Goldenberg et al. 2005b,  Vogel et al. 2005). Before systematic screening, effective 
prophylactic intervention or treatment for individuals with positive test results should be 
available. In addition, the test should be effi cient, with high sensitivity, specifi city and a 
high positive predictive value, and be of low cost. At present, despite all efforts, there are no 
accurate screening methods. Primary or secondary interventions to prevent PTD have also 
been largely unsuccessful. If an accurate marker of threatened PTD were to be available, 
it could be used to tailor intervention among individual women at risk, and management 
might be more successful (Vogel et al. 2005, Holst et al. 2009). In addition, defi nition 
of high-risk women among asymptomatic women would give better understanding of the 
pathophysiological pathways leading to PTD. This may provide an opportunity to develop 
methods to prevent PTD.
In women presenting with symptoms the cascade resulting in delivery has already started, 
and there may be no way to stop it, although delay may be possible. Among symptomatic 
women there are situations where prediction of PTD could be important and clinically 
helpful. The goal of early diagnosis of PTD in symptomatic women is the appropriate 
application of antenatal interventions that reduce perinatal morbidity and mortality: First, 
transfer of high-risk women with PTL to a facility with a neonatal intensive care unit. 
Second, administration of glucocorticoids to the mother at the right time for fetal lung 
maturation. Timing is desirable because the benefi t of glucocorticoids does not last beyond 
seven days (Murphy et al. 2001, Crowther and Harding 2007). Third, the use of tocolytic 
drugs to prolong pregnancy for a few days. The delay allows suffi cient time for maternal 
transfer and treatment with antenatal steroids. Because tocolytic drugs have signifi cant side 
effects, accurate diagnosis is important to avoid the risks and costs of unnecessary treatment. 
In cases with PPROM, antibiotic treatment may delay the delivery and reduce the incidence 
of chorioamnionitis and improve neonatal morbidity (Kenyon et al 2009). However, for 
symptomatic women with intact membranes antibiotic treatment is not recommended 
31
(King et al. 2009). Similarly, in women with group B β-haemolytic streptococci in the 
vagina, antibiotic treatment during labour reduces the rate of neonatal group B streptococcal 
sepsis, but not the rate of spontaneous delivery (Valkenburg-van den Berg et al. 2009). In 
addition, prediction of PTD among symptomatic women may enable physicians to avoid 
unnecessary hospitalization of women who have a low risk of premature delivery.
Predictive methods
Traditional methods
Traditionally, prediction of PTD is based on obstetric history, symptoms and epidemiological 
risk factors, with limited accuracy. Nevertheless, obtaining an accurate history is the 
fi rst step in identifi cation of high-risk women (Goldenberg et al. 1998, Iams et al. 1998, 
Goldenberg et al. 2003, Chandiramani and Shennan 2006). Classic digital examination, 
including assessment of position, effacement, softness and dilation of the cervix is used 
to create a Bishop score. Low predictive value and considerable intra- and inter-observer 
variability have limited the utility of the Bishop score (Copper et al. 1990, Onderoglu 1997, 
Iams et al. 2002, Owen et al. 2003). Furthermore, cervical effacement begins at the internal 
os and it is not possible to assess by digital palpation (Zilianti et al. 1995).
Several other risk-scoring systems have been developed, with poor sensitivity and 
specifi city (Creasy et al. 1980, Goldenberg et al. 1998). Thus most women who deliver 
preterm are not identifi ed by risk-scoring systems and most of those identifi ed as high risk 
do not deliver preterm. About 50% of women who experience PTD have no obvious risk 
factors. Furthermore, because traditional risk factor scores are based largely on previous 
obstetric history their accuracy is particularly low among women carrying their fi rst child; 
such women constitute approximately 50% of those affected by PTD (Goldenberg et al. 
1998, Iams 2003, Goldenberg et al. 2008). More sensitive and specifi c markers for the 
identifi cation of women at high risk of PTD are therefore needed. 
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Cervical assessment  by ultrasonography
The human cervix consists of smooth muscle cells (10–15%) and connective tissue (85–
90%) (Danforth 1983). Collagen bundles are at the highest ratio in the area of the internal 
os and provide the rigidity of the cervix (Leppert 1995, Kelly 2002). During pregnancy 
the cervix undergoes intensive remodelling of the extracellular matrix (ECM), including 
extensive changes in the concentration and composition of collagens, in two phases: 
ripening and dilatation (Leppert 1995). Cervical effacement and ripening begin, weeks 
before delivery, at about 32–36 weeks as regards term delivery and as early as at 16–24 
weeks in cases of PTD; the cervix softens, shortens, rotates anteriorly, and dilates. The 
pattern of changes varies between individuals (Rath et al. 1998, Bergelin and Valentin 
2002, Iams 2003). As the cervix effaces, the upper part (the internal os) opens and becomes 
indistinguishable from the lower segment of the myometrium (Kelly 2002).
The most accurate and reproducible method of cervical evaluation is transvaginal 
ultrasonography, with higher positive predictive value than digital palpation (Iams et al. 
2002, Owen et al. 2003). Three different ultrasonographic signs are considered. Signs of 
cervical incompetence are dilatation of the internal os, funnelling with protrusion of the 
amniotic membranes into the cervical canal and a short cervix in the absence of uterine 
contractions (Rozenberg et al. 2002, Owen et al. 2003). Dilatation of the internal os of > 
5 mm before 30 weeks of gestation is associated with premature delivery (Rozenberg et al. 
2002, Owen et al. 2003). The presence of funnelling shortens functional cervical length and 
increases the risk of spontaneous PTD (Rozenberg et al. 2002). Funnelling can be observed 
by ultrasonography even though digital cervical examination may indicate a long and 
closed cervix. In early and mid-pregnancy serial examinations of the cervix can be used to 
fi nd women at a high risk of PTD and those who might benefi t from intervention (Guzman 
et al. 1997). It has been reported that in asymptomatic women, at 22–24 weeks of gestation, 
cervical length of less than 25 mm is associated with a 5- to 6-fold increased risk of PTD 
before 34 weeks of gestation (Guzman et al. 1997, Andrews et al. 2000a, Iams 2003). The 
shorter the cervical length is, the greater the risk of PTD (Iams et al. 1996, Guzman et 
al. 1997, Iams et al. 1998, Andrews et al. 2000a). However, there is no agreement for the 
defi nition of a (sonographically) short cervix. Some authors have proposed a cut-off of 15 
mm and some 10 mm at mid-pregnancy in a subgroup of women at high risk of early PTD 
(Guzman et al. 1997, Macdonald et al. 1997, Norman 2007). However, the most common 
threshold used in asymptomatic women has been 25 mm between 20 and 24 weeks of 
gestation (Iams et al. 1996, Andrews et al. 2000a, Owen et al. 2003). Among symptomatic 
women, the most common threshold has been 15 mm, predicting spontaneous PTD within 
7 days of testing (Gomez et al. 1994, Tsoi et al. 2005). Altogether, the evidence supports the 
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idea that cervical competence is not a dichotomous variable with a specifi c cut-off point, 
but more likely a functional variable that can be evaluated by using a reproducible method 
during pregnancy with no apparent risks (Iams et al. 1996, Owen et al. 2003).
Biomarkers
A biomarker is defi ned as a biochemical substance in a body fl uid that by decreasing or 
increasing in concentration is likely to identify people at risk of a particular event (e.g. PTD). 
Biomarkers should be easy to collect at low cost and cause minimal risk and discomfort 
(Goldenberg et al. 2005b, Vogel et al. 2005). The sources of biomarkers for PTD include 
AF, urine, secretions in the vagina and cervical canal, serum and plasma. In addition, saliva 
and even fl uid taken from dental pockets of women with periodontal disease are used to 
predict PTD. Many biomarkers refl ect responses to infl ammation and some are infectious 
organisms (Vogel et al. 2005). All biomarkers can be measured in both asymptomatic and 
symptomatic individuals.
Obtaining cervical and vaginal secretions is easy and safe, with minimal discomfort for 
the woman.  However, many substances in vaginal and cervical fl uid are affected by 
various micro-organisms, which may limit their use. On the other hand many of these 
infective agents and their relationships to PTD have been evaluated in order to predict PTD 
(Goldenberg et al. 2005b). The most commonly studied predictors are BV and proteins 
such as fetal fi bronectin (FFN), insulin-like growth factor-binding protein-1 (IGFBP-1), 
and cytokines in cervical and vaginal fl uid. 
Many studies have been focused on infection in the amniotic fl uid. This contains substances 
of both maternal and fetal origin. The amniotic cavity is usually sterile as regards bacteria, 
and it does not contain white blood cells. Fewer than 1% of women not in labour at term 
have bacteria in the AF. The cell type most frequently recruited into the amniotic cavity 
during the course of an infl ammatory process is the neutrophil. They are thought to be 
of fetal rather than of maternal origin, refl ecting a fetal infl ammatory response (Romero 
et al. 1991, Sampson et al. 1997, Romero et al. 2006b, Goldenberg et al. 2008). As well 
as containing bacteria, AF in women with intrauterine infections has lower glucose 
concentrations, higher white cell counts and higher concentrations of various cytokines 
than AF of uninfected women. However, using substances in AF as markers of PTD 
requires an invasive examination, amniocentesis. This procedure carries a 0.5–1% risk 
of fetal loss, which minimizes its clinical use (Vogel et al. 2005). For this reason AF is 
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generally not obtained from asymptomatic women, except at the time of amniocentesis for 
genetic indications. This makes studies diffi cult to interpret and compare with other studies 
among symptomatic women (Goldenberg et al. 2005b). The use of AF is also limited by 
cost implications, and it causes discomfort to the patient.
Biomarkers in serum or plasma are easy to collect, with minimal discomfort to the patient. 
Alpha fetoprotein, ferritin, C-reactive protein, various cytokines and relaxin are examples 
of biomarkers that can be measured in serum and plasma and are used for predicting 
spontaneous PTD (Goldenberg et al. 2005b). 
Saliva is an ultrafi ltrate of plasma and among other biological fl uids it is the easiest to 
collect. Various hormones in saliva have been evaluated to predict subsequent PTD. The 
concentrations of steroid hormones in saliva are close approximates of the levels of unbound 
hormone in plasma, because unconjugated steroid hormones enter the saliva through 
diffusion. A limitation of the use of saliva for marker assessments is that various substances 
in the mouth can be confounding factors (Goldenberg et al. 2005b). In research work urine 
is used for measurements of some hormones and organisms predictive of PTD. Sexually 
transmitted diseases such as Chlamydia infection and gonorrhoea can be identifi ed by urine 
DNA examination (Andrews et al. 2000b).
Timing has to be considered when biological markers are used. It can be assessed by hour, 
day, week, or month before PTD and also in relation to gestational age. Some markers, 
for example fetal fi bronectin in cervicovaginal fl uid, can be powerful predictors in late 
pregnancy but less predictive in early pregnancy (Goldenberg et al. 1997, Goldenberg et al. 
2000). It is also important to understand when a marker turns positive in relation to PTD.  
Infl ammation-associated biomarkers
Infl ammation-associated proteins are produced in response to infl ammation in the 
choriodecidual space and also in extra-uterine tissues. Proteins of the choriodecidua are 
thought to leak into the AF, plasma or into cervical and vaginal fl uid from the placenta 
or choriodecidual space as a result of tissue disruption. Some proteins, IGFBP-1, FFN 
and prolactin, may have no actual role in the pathway leading to PTD but may serve as 
predictors, while substances such as cytokines and matrix metalloproteinases (MMP-8 in 
particular) are involved in pathophysiological mechanisms of PTD.  
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Insulin like growth factor-binding protein-1
Insulin-like growth factor-binding protein-1 is synthesized and secreted by fetal and adult 
liver cells and by decidualized endometrial cells during pregnancy. Progesterone and other 
factors that enhance decidualization induce IGFBP-1 production in the endometrium 
(Rutanen 2000). The physiological role of IGFBP-1 in pregnancy may be essential for 
proper endometrial/decidual function and endometrial-trophoblast interaction (Giudice 
and Irwin 1999). IGFBP-1 can either inhibit or enhance the effect of insulin like growth 
factors (IGFs). In maternal circulation, the concentration of IGFBP-1 increases during 
pregnancy, and in amniotic fl uid IGFBP-1 is a major protein from the second trimester 
onwards (Rutanen 2000).
The phosphorylation status of  IGFBP-1 varies in different body fl uids and tissues (Koistinen 
et al. 1993, Westwood et al. 1994, Martina et al. 1997). In AF, a non-phosphorylated isoform 
of  IGFBP-1 predominates, but in mid and late gestation phosphorylated isoforms, except for 
the most highly phosphorylated form are also present in AF. The concentration of IGFBP-1 
is 100–1000 times higher in AF than in maternal serum (Rutanen 2000). Human decidual 
cells secrete predominantly phosphorylated IGFBP-1(phIGFBP-1) isoforms, including 
the highly phosphorylated one, and decidual tissue is a source of phIGFBP-1 throughout 
pregnancy (Westwood et al. 1994, Martina et al. 1997, Rutanen 2000). Different patterns of 
IGFBP-1 phosphoisoforms, originating either from AF or the decidua, can be distinguished 
using specifi c monoclonal antibodies (Figure 6) (Rutanen 2000).
Figure 6.  Immunoblot (schematic) of IGFBP-1 with two different antibodies 
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Non-phosphorylated and less phosphorylated isoforms of IGFBP-1 in cervical and vaginal 
samples can be quantifi ed by immunoenzymometric assay using the monoclonal antibody 
6305 (Medix Biochemica, Kauniainen, Finland) (Figure 6) (Rutanen et al. 1996). Detection 
of AF isoforms in vaginal fl uid is used as a marker of ruptured fetal membranes (Rutanen 
et al. 1993, Lockwood et al. 1994) and a rapid bedside test (Actim PROM test, Medix 
Biochemica) is available for this purpose. The detection limit of this test is 25-50μg of AF 
isoforms per litre in a swab sample, (Rutanen et al. 1996). Urine and seminal plasma do not 
interfere in the test (Rutanen et al. 1993).
The phIGFBP-1 isoforms, including the highly phosphorylated isoform, can be detected in 
lower genital tract secretions by using the monoclonal antibody 6303 (Medix Biochemica) 
(Figure 6) (Nuutila et al. 1999). With tissue disruption in the choriodecidual space, due 
either to uterine contractions or infection-induced proteolysis, fetal membranes begin 
to detach from the decidua and cause leakage of decidual IGFBP-1 phosphoisoforms 
into the cervical and vaginal secretions (Rutanen 2000). In late pregnancy the increased 
concentrations of phIGFBP-1 (> 10 μg/l) in cervical secretions predict cervical ripening 
(Nuutila et al. 1999). The presence of phIGFBP-1 in the lower genital tract in early and 
mid-gestation has been poorly studied During medical termination of pregnancy, the 
concentration of phIGFBP-1 in cervicovaginal fl uid was found to increase, returning 
to undetectable in two weeks (Honkanen et al. 2004). In women with asyptomatic BV, 
elevated cervical fl uid concentrations of phIGFBP-1 in early pregnancy (10–17 weeks of 
gestation) have been associated with postpartum infectious complications (Kekki et al. 
1999). Elevated concentrations of phIGFBP-1 also predict neonatal infectious morbidity 
(Kurkinen-Raty et al. 2001).
Kekki et al. (2001) fi rst showed that a phIGFBP-1 concentration of at least 10 μg/l in 
cervical fl uid in the later half of pregnancy in symptomatic women indicated a 10-fold 
increased risk of PTD. An immunochromatographic rapid bed-side test for detection of 
phIGFBP-1 (≥10 μg/l) has been developed (Actim Partus test, Medix Biochemica). The 
test result is not affected by urine or seminal plasma (Rutanen 2000), but maternal blood 
may interfere, since the same phosphorylated isoforms of IGFBP-1 predominate in decidua 
and maternal blood (Martina et al. 1997).
The sensitivity of the rapid phIGFBP-1 test in the prediction of PTD among symptomatic 
women with singleton pregnancies varies between 66.7 and 100%, with a negative 
predictive value (NPV) between 88.0 and 100% (Table 1) (Lembet et al. 2002, Akercan et 
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al. 2004, Kwek et al. 2004, Elizur et al. 2005, Eroglu et al. 2007, Paternoster et al. 2007, 
Ting et al. 2007, Altinkaya et al. 2009 Paternoster et al. 2009, Tanir et al. 2009, Brik et 
al. 2010). Only one study included multifetal pregnancies, with no signifi cant difference 
between positive and negative results (Elizur et al. 2005). The sensitivity of the phIGFBP-1 
test has been shown to be highest in prediction of PTD within 7days (Lembet et al. 2002, 
Kwek et al. 2004, Ting et al. 2007).
Table 1.  Accuracy of rapid cervical fl uid phIGFBP-1 bedside test in prediction of spontaneous 
preterm delivery among symptomatic women
Study/Outcome Year N Testing wks Sensitivity % Spesifity % PPV % NPV %
< 48 hours
Lembet et al 2002 54 20-36 93.3 81.0 77.8 94.4 4.6 (1.9-11.3) 0.2 (0.04-0.6)
Kwek et al 2004 47 23-33 66.7 61.7 22.2 91.7 1.6 (0.8-3.2) 0.6 (0.2-1.8)
Ting et al 2007 94 24-34 100.0 74.0 18.0 100.0
Brik et al 2010 276 24-34 73.7 64.9 16.1 96.4 2.1 (1.5-2.9) 0.4 (0.2-0.9)
< 7 days
Lembet et al 2002 54 20-36 93.8 85.0 83.3 94.1 6.3 (2.2-17.9) 0.1 (0.01-0.5)
Kwek et al 2004 47 23-33 83.3 73.3 55.6 91.7 2.9 (1.5-5.5) 0.2 (0.1-0.8)
Ting et al 2007 94 24-34 69.0 78.0 39.0 92.0
Tanir 2009 68 24-37 93.3 79.2 56.0 97.6 4.4 (2.1-5.2) 0.8 (0.4-0.9)
Brik et al 2010 276 24-34 73.1 66.2 21.8 95.0 2.2 (1.6-3.0) 0.4 (0.2-0.8)
< 14 days
Ting et al 2007 94 24-34 72.0 80.0 46.0 92.0 3.6 0.4
Tanir 2009 68 24-37 60.7 80.0 68.0 74.4 2.8 (1.1-4.3) 0.4 (0.1-0.6)
< 32 wks
Brik et al 2010 276 24-34 76.2 65.5 18.4 96.4 2.2 (1.6-3.0) 0.3 (0.2-0.8)
< 34 wks
Tanir et al 2009 68 24-37 70.5 74.5 48.0 88.8 2.8 (1.1-3.8) 0.3 (0.1-0.9)
Brik et al 2010 276 24-34 59.0 66.0 23.4 88.6 1.8 (1.2-2.4) 0.6 (0.4-0.9)
< 35 wks
Elizur et al 2005 64 24-35 81.8 64.1 32.1 94.4 4.2 (1.4-12.0) 0.3 (0.03-3.4)
Erogu et al 2007 51 24-35 70.0 87.8 58.3 92.3 5.7 0.3
< 36 wks
Kwek et al 2004 47 23-33 73.7 82.7 77.8 79.2 3.9 (1.5-9.7) 0.3 (0.2-0.7)
< 37 wks
Kekki et al 2001 63 22-36 70.0 81.1 41.2 93.5 3.7 0.4
Lembet et al 2002 54 20-36 89.5 94.1 94.4 88.9 15.2 (2.3-102.5) 0.1 (0.03-0.4)
Akercan et al 2004 77 24-36 78.0 87.0 73.0 90.0 6.1 (2.3-15.8) 0.3 (0.1-0.7)
Elizur et al 2005 64 24-35 69.6 70.7 57.1 80.5 2.0 (0.7-5.9) 0.5 (0.2-1.7)
Pasternoster et al 2007 109 22-34 69.2 90.5 50.0 95.6  7.3 (3.6-15.0) 0.3 (0.2-0.8)
Altinkaya et al 2009 105 24-34 70.0 87.0 56.0 92.5 5.4 0.3
Pasternoster et al 2009 210 24-34 52.9 89.2 48.7 90.8 4.9 0.5
LR+ LR-
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In one study involving cervical ultrasonography and phIGFBP-1 in symptomatic women, 
both cervical length ≤ 26 mm (OR 7.37; 95% CI 2.27–23.96) and a positive phIGFBP-1 
test result (OR 15.7; 95% CI 3.95–58.18) were independent predictors of PTD (Paternoster 
et al. 2009). In another study, both short cervical length and phIGFBP-1 test results had 
similar negative predictive values, of 91.1 and 92.3% respectively (Table 2) (Eroglu et 
al. 2007). One study in asymptomatic women with a history of PTD showed that cervical 
length should be measured between 22 and 24 weeks of gestation, and the phIGFBP-1 test 
was most accurate when used at 30 weeks of gestation (Bittar et al. 2007). 
Table 2.  Accuracy of combinations of rapid cervical phIGFBP-1 bedside test with either 
cervicovaginal fetal fi bronectin (FFN) or cervical length in prediction of spontaneous PTD 
among symptomatic women
Study Year N Testing wks Test Outcome Sensitivity % Spesifity % PPV % NPV % LR + LR -
Ting et al 2007 94 24-34 phIGFBP-1 < 48 hours 100 74.0 18.0 100 3.8
< 7 days 69.0 78.0 39.0 92.0 3.2 0.4
< 14 days 72.0 80.0 46.0 92.0 3.6 0.4
FFN < 48 hours 60.0 72.0 11.0 97.0 2.1 0.6
< 7 days 56.0 76.0 32.0 89.0 2.3 0.6
< 14 days 61.0 78.0 39.0 89.0 2.8 0.5
Erogu et al 2007 51 24-35 phIGFBP-1 < 7 days 83.3 84.4 41.7 97.4   5.4 0.2 
FFN 83.3 80.0 35.7 97.3   4.2 0.2
CX < 20mm 66.7 95.6 66.7 95.6 15.0 0.4
CX < 25 mm 66.7 88.9 44.4 95.2   6.0 0.4
Cx <25mm + phIGFP-1 80.0 97.1 80.0 97.1 27.6 0.2
Cx <25mm + FFN 80.0 97.0 80.0 97.0 26.7 0.2
phIGFBP-1 < 35 wks 70.0 87.8 58.3 92.3 5.7 0.3
FFN 70.0 82.9 50.0 91.9 4.1 0.7
CX < 20mm 60.0 100.0 100.0 91.1 0.4
CX < 25 mm 60.0 92.7 66.7 90.5 8.2 0.4 
Paternoster et al 2009 210 24-34 phIGFBP-1 < 37 wks 52.9 89.2 48.7 90.8 4.9 0.5
CX < 26mm 86.4 71.9 34.5 96.8 3.1 0.2
CX < 26mm+phIGFBP-1 40.1 96.1 64.3 90.4 10.3 0.6
In low-risk asymptomatic pregnant women, both the sensitivity and the positive predictive 
value (PPV) of the phIGFBP-1 test have been found to be lower, but NPV was as high as in 
symptomatic women when tested between 20 and 37 weeks of gestation (Table 3) (Kekki et 
al. 2001, Bittar et al. 2007, Paternoster et al. 2007, Balik et al. 2008, Altinkaya et al. 2009). 
Table 3.  Accuracy of rapid cervical fl uid phIGFBP-1 bedside test in prediction of spontaneous 
PTD among asymptomatic women
Study Year N Testing wks Outcome (wks) Sensitivity % Spesifity % PPV % NPV % LR + LR -
Kekki et al. * 2001 58 22-37 < 37 94.7 98.1
Pasternoster et al 2007 223 22-34 < 37 22.2 91.8 11.8 96.0 2.7 0.8
Balic et al. 2008 80 24-34 < 37 80.0 93.3 44.4 98.6 11.9 0.2
Altinkaya et al 2009 73 24-34 < 37 40.0 82.3 14.3 94.9 2.3 0.7
* All delivered > 37 wks
39
Fetal fi bronectin 
Fibronectins are a family of ubiquitous glycoproteins found in the plasma and extracellular 
matrix. An oncofetal isoform of fi bronectin, fetal fi bronectin (FFN), synthesised by chorionic 
cells, is found in AF, placental tissue and extracellular matrix of decidua basalis next to 
the placental intervillous space (Lockwood et al. 1991, Honest et al. 2002). It is thought 
to adhere to the chorionic membrane of the blastocyst and the decidua (Lockwood et al. 
1991, Goldenberg et al. 1996, Goldenberg et al. 2000). It is thought to be released into the 
cervix and vagina from the choriodecidual interface through mechanical- or infl ammation-
mediated damage to the membranes or placenta before delivery. Fetal fi bronectin is present 
in high quantities in AF and in lesser quantities in maternal serum and cervicovaginal 
secretions (Vogel et al. 2005). It can be detected in cervicovaginal secretions before 20 
weeks of gestation (Goldenberg et al. 1997, Goldenberg et al. 2000). In an early study 
by Lockwood et al. (1991), 24% of cervical samples and 17% of vaginal samples had 
detectable FFN concentrations before 22 weeks of gestation. In another study, only about 
4% of pregnant women had detectable FFN concentrations in cervicovaginal secretions 
after 20 weeks of gestation (Goldenberg et al. 2000, Vogel et al. 2005). After 23 weeks of 
gestation, the presence of FFN (≥ 50 μg/l) in cervicovaginal samples from women with PTL 
predicts PTD (Lockwood et al. 1991, Goldenberg et al. 1997, Peaceman et al. 1997, Leitich 
et al. 1999, Honest et al. 2002). Fetal fi bronectin can be measured in samples obtained 
from the ectocervix or posterior vaginal fornix using an immunochromatographic test with 
a detection limit of ≥ 50 μg/l (Honest et al. 2002, Stafford et al. 2008). The accuracy of the 
FFN test in predicting spontaneous PTD varies (Honest et al. 2002). It is most accurate in 
predicting spontaneous PTD within 7–10 days after testing among symptomatic women 
(Honest et al. 2002, Goldenberg et al. 2003). A negative FFN test result rules out delivery 
within the next two weeks (NPV of 85–94%) (Rizzo et al. 1996, Goldenberg et al. 1997, 
Hincz et al. 2002, Honest et al. 2002, Goldenberg et al. 2003, Ting et al. 2007). A positive 
FFN test result at < 37 weeks of gestation in asymptomatic women increases the risk of 
spontaneous PTD 3- to 4-fold and in symptomatic women the risk is 6- to 7-fold increased 
(Honest et al. 2002). A repeat positive test result further increases the risk and a negative 
test result after a positive result lowers the risk to baseline (Goldenberg et al. 1997). 
The poor positive predictive value of the FFN test is the main reason why it is not 
recommended by the American College of Obstetricians and Gynecologists (ACOG) for 
routine screening, but only for screening of symptomatic women (ACOG 2001). The FFN 
test result may be affected by urine, seminal plasma and maternal blood, and it is not useful 
if the membranes have ruptured or if the woman has had sexual intercourse in the previous 
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24 hours (Shimoya et al. 1998, Honest et al. 2002). The concentrations of fetal fi bronectin 
in maternal serum are high in pre-eclampsia, perhaps as a result of endothelial damage 
(Madazli et al. 2005).
The accuracies of the phIGFBP-1 and FFN tests for predicting PTD are similar (Table 2) 
(Erogu et al. 2007, Ting et al. 2007).
Cytokines
Cytokines have been studied in maternal serum, AF and cervicovaginal secretions as protein 
biomarkers of PTD. They are low-molecular-weight proteins that mediate infl ammatory 
reactions by activating immune cells. In addition, cytokines coordinate production and 
secretion of antibodies, and other cytokines. Cytokines also participate in cell-to-cell 
communication and cellular activation (Vogel et al. 2005, Honest et al. 2009). They are 
released by many cells, including epithelial cells, endothelial cells and cells of the immune 
system.  Cytokines are generally classifi ed as either pro-infl ammatory (TNF-α, IL-1, IL-2, 
IL-3, IL-6, IL-8) or anti-infl ammatory (interleukin-4, -10 and -13) and they have a wide 
spectrum of biological activity in coordinating immune responses to infection (Goldenberg 
et al. 2005b, Vogel et al. 2005, Goldenberg et al. 2008). 
During pregnancy cytokines stimulate uterine contractions by production of prostaglandins 
and they are involved in preterm cervical ripening and PPROM by stimulation of 
metalloproteinases (Goldenberg et al. 2000, Slattery and Morrison 2002, Vogel et al. 2005, 
Goldenberg et al. 2008). Levels of interleukin (IL)-6 and IL-8 increase 10-fold in cervical 
tissue at term (Sennstrom et al. 2000). IL-8 and IL-1 promote recruitment and activation 
of neutrophils. Degranulation of neutrophils produces proteolytic enzymes which have 
a crucial role in cervical ripening. IL-8 and IL-1β induce hyaluronic acid production by 
human cervical fi broblasts (Osmers et al. 1995, Rath et al. 1998, Stygar et al. 2002). In 
addition, pro-infl ammatory cytokines such as IL-1β, IL-6, IL-8 and TNF-α protect the host 
against invading micro-organisms. This response can be both protective and harmful to 
the host (Keelan et al. 1999, Keelan et al. 2003). The pro-infl ammatory immune cascade 
is tightly regulated. Resolution of the infl ammatory process and healing occur through the 
activity of anti-infl ammatory cytokines such as interleukin-receptor antagonist. Imbalance 
between pro- and anti-infl ammatory responses has been implicated in the pathogenesis 
of infection-related premature delivery (Genc et al. 2004). PTD has been associated with 
elevated concentrations of IL-1, IL-6 and IL-8 even in amniotic fl uid in the absence of signs 
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of intrauterine infection (Arntzen et al. 1998).
The role of pro-infl ammatory cytokines in maternal serum and AF during infection and 
before parturition has been extensively studied. There are also studies which indicate 
that measuring cytokines in cervicovaginal fl uid could be of value in the prediction of 
intrauterine infection and PTD, especially close to delivery. High concentrations of IL-
1, IL-6, IL-8 and TNF-α in maternal serum, AF and cervicovaginal secretions predict 
PTD with variable accuracy. Comparison of these studies is diffi cult because of different 
defi nitions and thresholds of elevated concentrations (Lockwood et al. 1994, Foulon et al. 
1995, Ghidini et al. 1997, Wenstrom et al. 1998 Goepfert et al. 2001, Kurkinen-Raty et al. 
2001, Vogel et al. 2005, Honest et al. 2009). 
Recently the genetic polymorphism of cytokines has attracted attention (Holst and Garnier 
2008, Kalinka and Bitner 2009, Sata et al. 2009, Warren and Silver 2009). Genital tract 
immune hyporesponsiveness, as refl ected in low cervical concentrations of cytokines, may 
increase the risk of clinical chorioamnionitis (Simhan et al. 2003).
Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are genetically distinct but structurally related 
zinc-dependent metallopeptidases which can be classifi ed on the basis of their primary 
structures and substrate specifi cities into subgroups: collagenases (MMPs-1,-8–13), 
gelatinases (MMPs-2,-9), stromelysins (MMPs-3,7–10,-11) and membrane-type MMPs. 
MMPs can collectively degrade almost all extracellular matrix and basement membrane 
components, and process serpins, growth factors, pro- and anti-infl ammatory cytokines and 
chemokines, as well as modify apoptotic signals to regulate immune responses. They have 
been regarded as being important in various tissues with destructive, infl ammatory and 
malignant pathologies. MMPs are secreted in inactive forms and are inhibited by MMP-
specifi c tissue inhibitors. The expression of MMPs is attenuated through the expression of 
relaxins, integrins and extracellular matrix metalloproteinase inducer (EMMPRIN) (Sorsa 
et al. 2006, Weiss et al. 2007).
Matrix metalloproteinases are important mediators in the activation of labour at term but 
they also play an important role in pathological processes leading to PTD as well as in pre-
eclampsia and intrauterine growth restriction (Weiss et al. 2007). MMPs are also involved 
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as proteolytic enzymes in the perinatal complications of prematurity; chronic lung disease, 
necrotizing enterocolitis, intraventricular haemorrhage, cystic periventricular leukomalacia 
and retinopathy of prematurity (Cockle et al. 2007).
Matrix metalloproteinases  are believed to have two different roles in pregnancy. They are 
responsible for turnover and degradation of connective tissue proteins in the extracellular 
matrix (ECM) and they also affect the activity of various cytokines, consistent with their 
dual role in activation and inactivation of the infl ammatory system. During normal gestation 
MMPs-1,-2,-3,-7 and -9 are found in AF and fetal membranes. MMP-3, MMP-7 and MMP-
8 appear to be important in infl ammatory processes (Rath et al. 1998, Weiss et al. 2007). 
Collagenase 1 (MMP-1) is a physiological constituent of the AF. Parturition, whether term 
or preterm, has not been shown to be associated with an increase of MMP-1 in the AF. 
However, premature rupture of membranes (PROM) at term has been shown to be associated 
with lower concentrations of MMP-1 in the AF. In contrast, PPROM is associated with 
increased concentrations of MMP-1 (Maymon et al. 2000a, Weiss et al. 2007). Preterm 
cervical fi broblasts secrete more MMP-1 than term fi broblasts (Dubicke et al. 2008). 
The concentration of MMP-3 in AF is constant during pregnancy, but it increases during 
labour, whether preterm or term, or if infection is present. Spontaneous PROM (term or 
preterm) has no effect on MMP-3 concentrations (Weiss et al. 2007). In vitro, MMP-3 
secretion from preterm cervical fi broblasts is lower compared with term fi broblasts, 
suggesting that preterm and term cervical fi broblasts may have different phenotypes 
(Dubicke et al. 2008). MMP-7 in AF increases during gestation, but does not appear to play 
a major role in normal labour (Weiss et al. 2007). The results of one study indicated MMP-
7 expression in fetal membranes (amnion, chorion) and decidua with increasing activity in 
the amnion in cases with PROM at term, suggesting possible involvement of MMP-7 in 
PROM (Nishihara et al. 2008).
Gelatinases, both MMP-9 and MMP-2, are detectable in the AF in mid and the third 
trimester of pregnancy, suggesting that these MMPs have a physiological role in pregnancy 
(Maymon et al. 2000b). At labour, MMP-2 is dominant in the decidua while MPP-9 is 
responsible for gelatinolytic activity in membranes by degradation of the basement 
membrane and other extracellular matrix components (Weiss et al. 2007). The active form 
of MMP-9 increases in AF at the time of parturition (both term and preterm), while AF 
MMP-2 decreases at term but not in cases of PTD. The reason for this inverse relationship 
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between the two gelatinases is not known, but it suggests that these MMPs have different 
regulatory mechanisms (Maymon et al. 2000b). Maternal serum MMP-9 concentrations 
rise 24 h before the initiation of labour. Such late prediction is of little value in allowing 
initiation of preventive steps, but it can aid in understanding the mechanism of PTD (Tu et 
al. 1998).
 
Except for MMP-8 and MMP-9, the roles of MMPs in the prediction of delivery have not 
been studied. Recent fi ndings have indicated that there may be a genetic predisposition to 
PPROM mediated though polymorphisms of the MMP genes and their promoters (Romero 
et al. 2002, Crider et al. 2005, Srinivas and Macones 2005). 
Matrix metalloproteinase-8
Matrix metalloproteinase-8, a human neutrophil collagenase, or collagenase-2, was 
previously thought to be synthesized as a latent proenzyme only by specifi c granules of 
polymorphonuclear leukocytes, neutrophil precursors, during late myeloid maturation 
(Weiss 1989). It has recently become evident that a wide range of infl ammatory, 
mesenchymal, epithelial and malignant cells can also express MMP-8 (Van Lint and Libert 
2006). Furthermore, recent generation of MMP-8-defi cient mice has confi rmed that MMP-
8 is a central mediator in both acute and chronic infl ammation (Owen et al. 2004, Gueders 
et al. 2005, Kuula et al. 2009). MMP-8 is released from the cells on chemotactic stimulation 
during infl ammatory or infectious conditions. Neutrophil degranulation induced by pro-
infl ammatory or microbial factors is the key step in the regulation of MMP-8 concentrations. 
MMP-8 is activated by other proteases and oxidants in the extracellular milieu or at cell 
surfaces. Increased MMP-8 concentrations may refl ect either increased synthesis or release 
(Hanemaaijer et al. 1997, Maymon et al. 2000c, Owen et al. 2004, Sorsa et al. 2006, Van 
Lint and Libert 2006,). 
During pregnancy MMP-8 has been implicated in cervical ripening, rupture of membranes 
and intra-amniotic infection or infl ammation (Maymon et al. 2000c, Maymon et al. 2001b, 
Sennstrom et al. 2003, Nien et al. 2006, Kim et al. 2007). Cervical ripening is associated with 
infl ux of neutrophils. Neutrophils are a source of collagenase, and the cervix is dependent 
on collagen for its rigidity (Sennstrom et al. 2003). During cervical ripening, increased type 
I collagen turnover and processing result in a 30% reduction in collagen content compared 
with the non-pregnant state (Uldbjerg et al. 1983a, Uldbjerg et al. 1983b). Concentrations 
of MMP-8 correlate closely with cervical ripening and which it is primarily localized in 
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stromal tissue (Osmers et al. 1995a, Osmers et al. 1995b, Sennstrom et al. 2003, Dubicke 
et al. 2008). One study indicated concentrations of selected MMPs in the cervical mucus 
plug at term (Becher et al. 2004). MMP-8 turned out to be the most abundant MMP in the 
cervical mucus plug, with a mean concentration of 4.8μg/g. The role of MMP-8 in cervical 
fl uid has not been evaluated in the context of PTD.
Table 4.  MMP-8 concentrations in amniotic fl uid
Study Year N Testing weeks Patient characteristics p-value
Maymon et al 1999 25 15-17* I Intact membranes 2.1 (<0.06-32.7)
20-36 II PTL + intact membranes
19 II a PTL+ PTD < 37 wks + MIAC 208.1 (4.2-14600) ***
34 II b PTL+ term delivery 3.1 (<0.06-415.1) ** / ****
33 II c PTL+PTD < 37 wks 32.5 (<0.06-6006.6)
20-36 III PPROM
29 III a PPROM + MIAC 317.9 (2.16-14500) °
22 III b PPROM without MIAC 35.1 (0.71-1184.1)
? 37 IV Term delivery
25 IV a In labour 16.8 (0.33-1650) °°
25 IV b Not in labour 3.3 (< 0.06-38.6) °°°
20 ? 37 IV c Term PROM, Not in labour 5.6 (0.22-19.8)
Maymon et al 2001 371 20-36 Intact membranes
200 PTD < 36 wks 19.5 (<0.06-16600) <0.001
171 Delivery ? 36 wks 2.1 (<0.06-500.0)
34 Microbial invasion 605.6 (0.65-15000) <0.001
337 No microbial invasion 10.6 (<0.06-16600)
20 Neonatal death 1048.3 (10.65-16600.0)
351 No neonatal death 12.5 (<0.06-14750.0) <0.001
Maymon el al 2001 101 24-36 PPROM
37 Adverse neonatal outcome 54.4 (0.82-14500) <0.05
64 No adverse neonatal outcome 28.9 (0.78-2451.8)
46 Microbial incasion 143.8 (1.83-14500) 0.003
55 No microbial incasion 23.2 (0.28-6006.7)
Yoon et al 2001 114 16-23.3 Intact membranes
19 PTD < 32 wks 3.1 (0.3-1954.9) <0.01
95 Delivery > 37 wks 1.3 (<0.3-45.2)
PTL = Preterm labour
PTD= Preterm delivery
MIAC= Microbial inavasion of the amniotic cavity
*       All delivered at term
**     II b /II c,  p< 0.05
***   II a / II c, p <0.001
**** II b / II c, p =0.003
°     III a /III b, p< 0.01
°°   IV a / IV b, p= 0.06
°°° IV b /IV c, p= 0.9
             MMP-8 μg/l 
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Matrix metalloproteinase-8 in AF has been studied extensively in recent years. Its 
concentrations are elevated in AF in women who experience spontaneous PPROM, 
microbial invasion of the amniotic cavity (MIAC), and spontaneous PTL, suggesting that 
increased AF-specifi c MMP-8 concentrations could be used to identify women who are at 
risk of PTD and adverse neonatal outcome (Maymon et al. 2000c, Angus et al. 2001). In 
addition, correlations between MMP-8 and leukocytes in AF as well as between MMP-8 and 
MMP-9 have been found (Maymon et al. 2000c). Amniotic fl uid MMP-8 concentrations are 
elevated not only in women with intra-amniotic infection and intact membranes, but also 
in those who deliver preterm with negative AF cultures (Table 4) (Maymon et al. 2001a, 
Nien et al. 2006). Elevated MMP-8 concentrations (≥ 23–30 μg/l) are also associated with 
adverse neonatal outcome after adjustment for gestational age at birth and other confounding 
variables, including microbial invasion in the AF (Maymon et al. 2001a, Maymon et al. 
2001b, Nien et al. 2006, Kim et al. 2007). In addition, recent evidence demonstrates that 
patients with intra-amniotic infl ammation but negative microbiological culture results 
have outcomes similar to those among patients with positive culture results, which may 
refl ect adverse effects of the fetal infl ammatory response (Maymon et al. 2001b, Yoon et 
al. 2001, Shim et al. 2004). Therefore, it has been thought that in patient management, 
detection of signs of infl ammation in the AF may be more practical than the detection of 
infection (Shim et al. 2004). Moymon et al. have demonstrated that a combination of three 
tests, white blood cell count (> 30 cells/mm³), Gram staining and assay of AF MMP-8 (> 
30 μg/l), represents the most sensitive method for prediction of a positive AF culture in 
patients with PTD and intact membranes (Maymon et al. 2001a). In cases with PPROM 
the combination of white blood cell count (> 30 cells/mm³), assay of interleukin-6 (> 17 
μg/l), Gram staining and assay of MMP-8( > 30 μg/l) showed the highest performance in 
the prediction of PTD (sensitivity 88.4%, specifi city 48.4%, PPV 63.3% and NPV 80.8%) 
(Maymon et al. 2001b). In these two studies a concentration of MMP-8 < 30 μg/l alone had 
the highest negative predictive value (97.7% and 75.6% respectively) for microbial invasio 
of the amniotic cavity (Table 5) (Maymon et al. 2001a, Maymon et al. 2001b).
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Table 5.  Test performance and odds ratios of selected biomarkers of intra-amniotic 
infection, infl ammation and preterm delivery 
Study Year N
Testing 
weeks
Membranes 
status Outcome Test results Sensiv Spesif PPV NPV LR+ LR-
Maymon et al 2001 371 20-36 Intact
34 MIAC
MMP-8 > 30 μg/l 82.4 78.0 36.0 97.7 3.7 0.2
Gram stain 32.4 97.6 57.9 93.3 13.5 0.7
WBC > 30 cells/mm³ 52.9 91.1 38.3 94.9 5.9 0.5
IL-6 > 17 μg/l 62.0 90.0 30.5 94.3 6.2 0.4
Maymon et al 2001 101 24-36 Ruptured
46 MIAC
MMP-8 > 30 μg/l 76.1 61.8 62.0 75.6 2.0 0.4
WBC > 30 cells/mm³ 44.4 83.6 69.0 64.8 2.7 0.7
IL-6 > 17 μg/l 40.6 92.3 81.3 65.5 5.3 0.6
37 ANO
MMP-8 > 30 μg/l 65.8 50.8 44.6 71.1 1.3 0.7
IL-6 > 17 μg/l 34.6 84.4 56.3 69.1 2.2 0.8
WBC > 30 cells/mm³ 34.2 74.2 44.8 64.8 1.3 0.9
Yoon et al 2001 114 17-22.3 Intact PTD < 32 wks
19 MMP-8 > 23 μg/l   * 42.0 99.0 88.9 89.5 42.0 0.6
IL-6 > 0.6 μg/l  ** 42.0 92.0 50.0 88.8 5.3 0.6
Angiogenin > 13.85 μg/l  *** 37.0 87.0 36.8 87.4 2.8 0.7
Nien et al. 2006 327 22-35 Intact
PTD
38 < 48h   MMP-8 > 23 μg/l 61 97.00 70.0 95.0 20.3 0.4
66 <7 d   47 99.0 94.0 88.0 47.0 0.5
80 <14 d   39.0 99.0 94.0 83.0 39.0 0.6
32 < 32 wks   56.0 98.0 86.0 89.0 28.0 0.5
61 < 34 wks   44.0 98.0 87.0 86.0 22.0 0.6
24 MIAC 83.0 95.0 56.0 99.0 16.6 0.2
38 IAI IL- 6 > 2.6 μg/l 84.0 99.0 89.0 98.0 84.0 0.2
Lee et al 2008 155 Variable
29 MIAC
Positive MMP-8 test ( ? 10ng/ml)   ª 86.2 74.6 43.9 95.9 3.4 0.2
WBC >19cells/mm³   ªª 75.9 80.2 46.8 93.5 3.8 0.3
Glugose < 17mg/dl   ªªª 58.6 76.2 36.2 88.9 2.5 0.5
Kim et al 2007 141 20.4-34.9 Ruptured
60 IAI / I IL-6 > 2.6 μg/lPositive MMP-8 test ( ? 10μg/l) 90.0 80.2 77.1 91.5 4.6 0.1
25 IA infection 92.0 59.5 32.9 97.2 2.3 0.1
MIAC= Microbial invasio of the amniotic cavity *  OR 68.4 (95% CI 7.8-599.0)
MMP-8 = Matrix metalloproteinase 8 **  OR 7.9 (95% CI 2.5- 25.3)
WBC= White blood cells ***  OR 4.0 (95% CI 1.3-12.3)
IL = interleukin
PTD= Preterm delivery ª OR 18.4 (95% CI 5.9-56.8)
IAI = intraamniotic inflammation without microbial invasion ªª OR 12.7 (95% CI 4.9-33.0)
ANO = Adverse neonatal outcome ªªª OR 4.5 (95% CI 1.9-10.6)
IA = intraamniotic 
Recently, a bedside test has been developed for the diagnosis of intra-amniotic infl ammation 
based on the detection of elevated concentrations of MMP-8 in AF (SK Pharma Co. Ltd, 
Kyunggi-do, Korea) (Nien et al. 2006). The prevalence of a positive MMP-8 test result ( 
≥ 23 μg/l) in AF among women with PPROM has been found to be 50%, but it was only 
11% in women with PTL and intact membranes (Nien et al. 2006). This rapid bedside test 
for MMP-8 has a sensitivity of 56% and a specifi city of 98% for predicting PTD at < 32 
weeks of gestation. The test allows identifi cation of patients with intra-amniotic infection 
with a sensitivity of 83% and a specifi city of 95% and identifi cation of infl ammation 
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with a sensitivity of 84% and a specifi city of 99% among patients with spontaneous PTL 
and intact membranes (Nien et al. 2006). Lee et al. showed that the MMP-8 rapid test is 
more sensitive (86.2%), with a high negative predictive value (95.9%) in the diagnosis of 
microbial invasion of the amniotic cavity than the commonly used glucose test and white 
blood cell count in AF (Lee et al. 2008b). Moreover, an elevated MMP-8 concentration in 
AF with or without microbial invasion is associated with a shorter amniocentesis–delivery 
interval in patients with intact membranes or with PPROM (Maymon et al. 2001a, Maymon 
et al. 2001b, Shim et al. 2004, Kim et al. 2007, Kim et al. 2007).
Biggio et al. analysed AF MMP-8 at the time of genetic amniocentesis between 14 to 21 
weeks of gestation. An elevated level of MMP-8 (above the 90th  percentile) was highly 
associated with subsequent PPROM compared with normal term delivery, suggesting 
that the physiological processes that contribute to PPROM may begin in early pregnancy 
(Biggio et al. 2005). 
Other biomarkers 
Several biomarker have been studied for prediction of PTD, but none of them are in clincal 
use for that purpose.
Prolactin is produced by the decidua, maternal adenohypophysis and fetal pituitary during 
pregnancy. Tissue disruption in the choriodecidual space, mechanical or due to infection 
or infl ammation, may lead to leakage of prolactin into the cervix and vagina (Honest et 
al. 2009). Threshold values for prolactin vary, making it diffi cult to compare data. In two 
studies among symptomatic women the threshold was 2.0ng/ml in cervicovaginal secretion. 
The positive predictive value was 36–80% and the negative predictive value 65–94% for 
prediction of PTD at < 34 weeks of gestation (Jotterand et al. 1997, O’Brien et al. 1994).
Pregnancy-associated plasma protein-A (PAPP-A) is a glycoprotein which is secreted 
from the trophoblastic cells of the placenta. It is generally assayed in conjunction with 
ultrasonographic measurement of nuchal translucency (NT) and assay of free β-human 
chorionic gonadotrophin (β-hCG) as part of screening programmes for trisomy 21 and other 
forms of aneuploidy in the fi rst trimester (Dugoff et al. 2004, Malone et al. 2005). Low 
concentrations of maternal serum PAPP-A are associated, in the absence of an abnormal 
karyotype, with an increased (twofold) risk of PTD (Smith et al. 2006, Spencer et al. 2008) 
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and when there was a low level of PAPP-A together with a high level of alpha fetoprotein 
the risk increased to 9.9-fold (95% CI 4.4–22.0)(Smith et al. 2006). A similar predictive 
value has not been found by using a combination PAPP-A and C-reactive protein (CRP) 
in maternal serum or AF (Ozer et al. 2005). Low maternal serum PAPP-A concentrations 
during the fi rst trimester may refl ect a trophoblast invasion defect at the maternal-fetal 
interface, resulting in subsequent PTD, particularly in cases with PPROM (She et al. 2007).
Corticotrophin-releasing hormone (CRH) is a principal regulator of the hypothalamic-
pituitary-adrenal (HPA) axis. During pregnancy CRH is produced in the syncytiotrophoblast, 
decidua and fetal membranes and secreted into the maternal circulation. CRH drives the 
pituitary-adrenal axis to produce increased amounts of cortisol during the latter half of 
normal pregnancy, so that its concentrations increase more than 20-fold during the 5 weeks 
before delivery (Campbell et al. 1987, Hillhouse and Grammatopoulos 2002, Linton et al. 
1993). Elevated plasma CRH concentrations as early as at 18 to 20 weeks of gestation are 
causally related to PTD, refl ecting exposure to stress, hypoxaemia or infl ammation (Hobel 
et al. 1999, Majzoub and Karalis 1999, Ellis et al. 2002). CRH is diffi cult to quantify, with 
large inter-individual variation. For that reason it is not in clinical use as a single marker of 
PTD (Vogel et al. 2005).
Alpha- fetoprotein (AFP) in maternal circulation during pregnancy is believed to be mainly 
of fetal origin. Elevated concentrations of AFP are commonly associated with structural 
fetal anomalies including congenital nephrosis and neural tube and abdominal defects 
(Chandra et al. 2003). Elevated concentrations of maternal serum AFP (≥ 2 MOM) at 14–
24 weeks of gestation among asymptomatic women (without fetal neural tube defects) 
have been associated with PTD, with a 3- to 5-fold risk of delivery at less than 37 weeks 
(Heinonen et al. 1996, Tikkanen et al. 2007, Yuan et al. 2009). AFP is not useful as a single 
marker, but it is in the context of other markers of abnormal pregnancy (Vogel et al. 2005, 
Yuan et al. 2009). 
Beta human chorionic gonadotrophin (β-hCG), produced by the fetal-placental unit, 
is present in maternal serum and AF, but concentrations in AF are much lower than in 
maternal serum during pregnancy. Commonly, serum concentrations are measured in the 
second trimester to screen for chromosomal abnormalities (Dugoff et al. 2005). In cases 
of normal chromosomes, elevated β-hCG may be associated with adverse pregnancy 
outcomes, such as early fetal loss, PTD, and pre-eclampsia. In addition to AF and maternal 
serum, β-hCG is measurable in cervicovaginal secretion, where it leaks after disruption 
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in the choriodecidual space (Honest et al. 2009). After exclusion of fetal chromosomal 
abnormalities and pregnancy complications such as pre-eclampsia, placental abruption 
and rupture of fetal membranes, elevated levels of cervical β-hCG in symptomatic women 
predict spontaneous PTD (Guvenal et al. 2001, Sanchez-Ramos et al. 2003, Gurbuz et al. 
2004). The β-hCG cut-off level in maternal serum for adverse perinatal outcome is usually 
≥ 2 MOM, but the value as regards predicting PTD is lower in asymptomatic women 
(Morssink et al. 1998, Spencer 2000, Yaron et al. 2002, Chandra et al. 2003, Tikkanen et al. 
2007, Spencer et al. 2008). Measurement of β-hCG in any fl uid cannot be used as a single 
marker of PTD, but it can perhaps be used in combination with other markers. 
Relaxin in human pregnancy is both a systemic hormone from the corpus luteum and an 
autocrine/paracrine hormone at the maternal-fetal interface formed by the decidua, placenta 
and fetal membranes. Measurement of maternal serum relaxin in the fi rst half of pregnancy 
among asymptomatic women can predict spontaneous PTD (1.5-fold increase) (Weiss et al. 
1993, Vogel et al. 2002, Vogel et al. 2006). In one study among symptomatic women serum 
relaxin was shown to predict PTL and spontaneous PTD (Vogel et al. 2002). However, 
relaxin has not turned out to be a clinically useful predictor of PTD.
C-reactive protein (CRP), produced by hepatocytes, is an acute-phase reactant associated 
with the presence of systemic infections and may indicate a risk of spontaneous PTD. 
It is an easily detectable and reliable marker. CRP concentrations in serum in the fi rst 
trimester, including highly sensitive CRP, has not been found to increase the estimated risk 
of PTD (Karinen et al. 2005, Tikkanen et al. 2008). Among symptomatic women, CRP 
concentrations in serum have been found to have low sensitivity (38%) but high specifi city 
(94%) in predicting PTD at < 34 weeks of gestation (Foulon et al. 1995).
Thrombin is a coagulation factor which is a multifunctional protease capable of inducing 
myometrial contractions. This enzyme has been implicated in PTL. A second trimester 
plasma thrombin-antithrombin concentration of > 3.9 μg/l predicts subsequent PPROM, 
with a sensitivity of 88% and specifi city of 68%. Thrombin may become a new predictor 
of adverse pregnancy outcome (Rosen et al. 2001, Chaiworapongsa et al. 2002). So far, 
thrombin has not been used in a clinical context for prediction of PTD.
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AIMS OF THE STUDY
The present study was undertaken to analyse whether or not the biochemical markers 
phIGFBP-1 and MMP-8, measured in vaginal and cervical fl uid in early and mid-pregnancy, 
can be used to identify women at high risk of subsequent spontaneous PTD.  
The specifi c aims were to: 
1. Measure the concentrations of phIGFBP-1 in vaginal and cervical fl uid, 
 and examine factors which may affect the concentrations of this biomarker in the 
 lower genital tract during the fi rst and mid-second trimester of pregnancy
2. Evaluate whether elevated cervical fl uid phIGFBP-1 concentrations in 
 asymptomatic women in the fi rst or mid-second trimester are associated with 
 subsequent spontaneous PTD 
3. Assess the accuracy of ultrasonographic cervical length measurement and the rapid 
 cervical phIGFBP-1 test separately and in combination in the prediction of PTD 
 among women with self-reported uterine contractions in later pregnancy
4. Measure MMP-8 concentrations in vaginal and cervical fl uid, and examine factors 
 that affect MMP-8 concentrations in the lower genital tract during the fi rst and 
 mid-second trimester of pregnancy
5. Evaluate whether cervical fl uid MMP-8 concentrations in asymptomatic women in 
 the fi rst and second trimester are associated with subsequent spontaneous PTD
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SUBJECTS AND METHODS
Subjects
The studies were conducted with the approval of the Ethics Committee of the Department 
of Obstetrics and Gynaecology, Helsinki University Hospital (Dnro 49/E8/05). The 
Department of Obstetrics and Gynaecology includes three different hospitals (the Maternity 
Hospital, the Women’s Clinic and Jorvi Hospital) and each of them has a Maternity Clinic. 
The study population was enrolled and data collected between April 2005 and December 
2006. Overall information concerning the prospective study was mailed to 15,641 
consecutive pregnant women who had registered for routine ultrasonographic screening 
as part of routine antenatal care in the fi rst trimester (between 12+0 and 13+6 weeks of 
gestation, based on the last menstrual period) and in the second trimester (between 18+0 
and 20+6 weeks of gestation). Gestational age was confi rmed or corrected at the fi rst 
ultrasonographic examination and used accordingly at the second screening. A total of 5180 
(33.0 %) volunteers participated in the study and signed an informed consent document 
(Figure 7). Subjects and outcomes of each study are shown in table 6. In every study all 
women had intact fetal membranes, based on history and speculum examination and none 
had vaginal bleeding at the time of examination.
Figure 7.  Study population
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Table 6.  Subjects and outcomes in each study
Study Year Stage of pregnancy Subjets Outcomes PTD (%) Term delivery
I 2005-2006 First trimester 1690
Second trimester 1607
II 2005-2006 First trimester 4984 < 32 wks 26 (0.5) 4958
4984 < 37 wks 189 (3.8) 4795
Second trimester 4630 < 32 wks 21 (0.5) 4609
4630 < 37 wks 167 (3.6 4463
III 2005-2006 22-34 wks 246 ? 34wks 10 (4.1) 236
IV 2005-2006 First trimester 1979
Second trimester 1950
V 2005-2006 First trimester 4855 < 37 wks 184 (3.9) 4671
Second trimester 4671 < 37 wks 164 (3.5) 4407
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Study I
Study I dealt with phIGFBP-1. It included participants from the Maternity Hospital. The 
study population is shown in fi gure 8.
The outcome measures were phIGFBP-1 concentrations in the vaginal and cervical fl uids 
separately and the associations between phIGFBP-1 concentrations of ≥ 10 μg/l and selected 
factors. The selected factors were age, parity, gestational age at examination time, vaginal 
pH, cervical length, history of sexual intercourse less than 48 hours before the examination, 
history of vaginal bleeding during the current pregnancy, history of the use of antibiotics 
during the current pregnancy and the type of pregnancy (single or abnormal). Women with 
multiple gestation were excluded.
Figure 8.  Study I population
Study II and Study V
Study II dealt with phIGFBP-1 and Study V with MMP-8. A total of 5180 pregnant women 
participated in Study II and V. The study populations are shown in fi gure 9. The outcome 
measure was spontaneous PTD at < 32 weeks of gestation and at < 37 weeks of gestation in 
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Study II and spontaneous PTD at < 37 weeks of gestation in Study V (Table 6). Spontaneous 
PTD was defi ned as PTD after the spontaneous onset of contractions or PPROM, regardless 
of whether the delivery was vaginal or by Caesarean section, or in the case of membrane 
rupture, induced.
Figure 9.  Study II and V populations
Study III
The study group consisted of a total of 249 women with singleton pregnancies who 
presented at an emergency antenatal clinic with self-reported uterine contractions and 
intact membranes at any time between 22 and 34 weeks of gestation. The study population 
was collected from all three participating hospitals of the Department of Obstetrics and 
Gynaecology. The presence of uterine contractions was confi rmed by external tocography, 
but no strict defi nition for the frequency or intensity of the contractions was set. Other 
inclusion criteria were a) no known major fetal anomalies, b) no vaginal bleeding at 
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presentation, c) no placenta praevia, and d) signed informed consent. Three patients were 
excluded because they delivered prematurely as a result of severe pre-eclampsia. Thus, the 
fi nal study sample included 246 women (Table 6). All women had intact fetal membranes, 
based on history and speculum examination. 
The outcome measures were spontaneous PTD (after spontaneous onset of contractions or 
spontaneous rupture of the membranes, regardless of whether delivery was vaginal or by 
Caesarean section) at ≤ 34 weeks of gestation and delivery within 14 days of examination. 
The median time interval from initial evaluation to delivery was also calculated.
Study IV
Study IV dealt with MMP-8. The study included all participants in the Maternity Hospital. 
The study population is shown in fi gure 10. The outcome measures were the MMP-8 
concentrations in vaginal and cervical fl uids and the associations between MMP-8 and 
selected factors. The selected factors were age, gravidity, parity, cervical length, type 
of pregnancy (single, twin or abnormal), gestational age at examination time, bacterial 
vaginosis, vaginal leukocytosis and candidiasis.
Figure 10.  Study IV population
57
58
Methods 
Collection of clinical data
Relevant clinical data were recorded from hospital charts and by interviewing. The same 
person interviewed and examined all participants in Studies I and IV. In Studies II and 
V ultrasonographic screening was carried out by midwives who also interviewed and 
examined all study participants. Before the fi rst ultrasonographic screening, between 12+0 
and 13+6 weeks of gestation, gestational age was assessed on the basis of the time of the 
last menstrual period. Final gestational age was confi rmed at the fi rst ultrasonographic 
examination and used accordingly at the second screening, between 18+0 and 20+6 weeks 
of gestation. 
The type of pregnancy was diagnosed by ultrasonography at the fi rst screening. Types were 
recorded as single, multiple and abnormal pregnancies. Women with multiple gestations 
were included in Studies II, IV and V.
In Studies I, II, IV and V a history of obvious vaginal bleeding before the fi rst examination 
or between the fi rst and the second examination, use of oral antibiotics during the last four 
weeks and sexual intercourse during the last 48 hours before examination were asked about 
and recorded. The physician who examined the patient in the emergency obstetric clinic 
in Study III took the study samples and asked about a history of previous bleeding, but 
information on sexual intercourse was asked about via questions enclosed in envelopes.  
Measurement of pH in vaginal smears (Study I) was performed by using indicator sticks 
(Macherey-Nagel Gmb&Co, phFIX 3.6-6.1) at both screenings. For statistical analysis, the 
pH readings were divided into categories: < 4.7 and ≥ 4.7. 
Cervical length (Studies I, III, IV) was measured by using a Hitachi EUB-5500 ultrasound 
machine (EUP-V53W) (Hitachi Medical Corp., Tokyo, Japan) equipped with a 5–9 MHz 
transvaginal probe, which was inserted into the vagina and placed in the anterior fornix 
after the woman had emptied her bladder. Cervical length was measured as the length of 
the cervical canal from the external os to the internal os in a sagittal plane view. Three 
measurements were performed and the shortest measurement associated with the best 
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image was recorded as the length of the cervix. Cervical lengths of < 25 mm (Study III) 
and < 30 mm (Studies I, IV) were used to defi ne a short cervix. The presence or absence of 
funnelling, defi ned as a protrusion of the amniotic membranes into the cervical canal, was 
considered. In the fi rst study a print was taken at each measurement and the technically 
best, shortest distance was recorded. All scans were carried out by one midwife (Study I 
and IV), and the fi rst 100 cervical measurements were performed under the guidance of 
a physician. Intra-observer variation was found to be 4–10%. In addition, an experienced 
sonographer checked the fi rst 150 prints to confi rm the validity of the imaging and 
measurement technique. In Study III, the physicians at the emergency obstetric clinic 
examined the patient and measured cervical length.
Deliveries before 32 and 37 completed gestational weeks were defi ned as preterm in Study 
II. In Study V we used 37 gestational weeks as a limit for PTD. In Study III the outcome 
measure was delivery at ≤ 34 weeks, which is the upper limit for tocolysis in our hospital, 
and within 14 days of examination. Spontaneous PTD was defi ned as delivery preceded 
by spontaneous onset of uterine contractions with intact membranes, or spontaneous 
PPROM in the absence of contractions, regardless of whether the delivery was vaginal 
or by Caesarean section, or in the case of membrane rupture, induced. Iatrogenic preterm 
deliveries induced by physicians for maternal or fetal indications were excluded.  
Body mass index (kg/m²), smoking status and history of previous PTD and in vitro 
fertilisation (IVF) (Studies II and V) were obtained from the forms fi lled for each pregnancy 
by the National Institute for Health and Welfare, Finland. BMI > 30 kg/m² was used as 
a cut-off for a markedly overweight condition. All women who smoked in the fi rst and 
second trimester were defi ned as smokers. Women who had been subjects in assisted 
reproductive technology were placed in the IVF category. Assisted conception referred 
to women who had undergone ovulation induction, intrauterine insemination, standard in 
vitro fertilisation or intracytoplasmic sperm injection. Women of ≥ 37 years (Study V) were 
defi ned as “old” when pregnant.
Information regarding the current pregnancy, such as use of corticosteroids, tocolysis, 
hospital admission and puerperal infections during the hospital stay were obtained from 
the patient’s hospital records (Study III). The examining physician made the decision 
concerning admission and management based on the patient’s obstetric history, presence 
of other risk factors, symptoms and clinical fi ndings, including ultrasonographic fi ndings. 
Tocolytic agents (intramuscular or intravenous β-sympathomimetic agents, oral calcium-
60
channel blockers or an intravenous oxytocin receptor antagonist) were given when clinically 
indicated. Corticosteroids were given for fetal lung maturation. Puerperal infection was 
defi ned by standard clinical and laboratory criteria, including fever of > 38 °C, tenderness of 
the uterus and purulent discharge, elevated C-reactive protein concentration and leukocyte 
count. Cultures for Chlamydia trachomatis and Streptococcus agalactiae were performed 
when clinically indicated (Study III) and recorded. 
Data on pregnancy complications and delivery were collected from the patients’ hospital 
records (Studies I–V).  
Samples and assays
Immunoenzymometric assay (IEMA) of phIGFBP-1 (I, II, III)
Swab samples of cervical and vaginal fl uids for phIGFBP-1 measurement were obtained 
before any other procedure. One swab was kept in the external part of the cervix, and one in 
the side- or posterior fornix of the vagina simultaneously for about 20 seconds. Thereafter, 
each swab was placed in a test tube containing 0.5 ml of extraction buffer and it was 
rinsed in the buffer for 10–15 seconds. The polyester swabs absorb approximately 150 μl 
of fl uid when saturated, and the average dilution of the vaginal/cervical sample in the buffer 
is approximately 1:5. The specimens were frozen and stored at -20 °C until phIGFBP-1 
concentrations were measured by immunoenzymometric assay, using monoclonal antibody 
6303 as the detecting antibody (Medix Biochemica, Kauniainen, Finland). This antibody 
detects all phosphorylated isoforms, including the highly phosphorylated isoform, which 
is produced by the decidua and is not present in AF (Martina et al. 1997, Rutanen 2000). 
The detection limit of the assay was 0.3μg/l. All samples were measured in duplicate. 
When exploring factors that may infl uence phIGFBP-1 concentrations in the vagina and 
cervix, a concentration of phIGFBP-1 ≥ 10 μg/l (Studies I and II) was considered elevated, 
as in previous studies (Nuutila et al. 1999, Kekki et al. 2001). A cut-off of 10μg/l is also 
the detection limit of the bedside test (Actim Partus test, Medix Biochemica, Kauniainen, 
Finland). The rapid bedside test of phIGFBP-1 was used in Study III. The laboratory staff 
were blinded to the clinical status of the patients, and the phIGFBP-1 test results were not 
available to the physician.  
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Immunofl uorometric assay (IFMA) of MMP-8 (IV, V)
For MMP-8 measurement, one swab was kept in the external part of the cervix and one 
in the posterior vaginal fornix for about 20 seconds. Thereafter, each swab was placed 
in a test tube containing 0.5 ml of extraction buffer and rinsed in the buffer for 10–15 
seconds. The polyester swabs absorb approximately 150 μl of fl uid when saturated, and 
the average dilution of the vaginal/cervical sample in the buffer is approximately 1:5. The 
specimens were frozen and stored at -20 °C until MMP-8 concentrations were measured 
by time-resolved immunofl uorometric assay (IFMA) in a single laboratory (Wallac,Turku, 
Finland) (Hanemaaijer et al. 1997, Tuomainen et al. 2007). This assay detects pro- and 
active MMP-8 as well as MMP-8 complexed with tissue inhibitors or α-2-macroglobulin. 
Vaginal/cervical samples were further diluted to 1:10 prior to assay. First, standards and 
samples diluted in DELFIA® buffer were incubated in anti-MMP-8-coated wells of a plate 
for 1 hour. After washing, Eu-labelled anti-MMP-8 antibody diluted in DELFIA buffer was 
added to the wells and the plate was incubated for 1 hour. After washing again, DELFIA 
Enhancement solution was added and fl uorescence was measured using VICTOR™ 2D 
equipment. The sensitivity of the assay was at least 0.08μg/l.
Bacterial vaginosis (III, IV)
Vaginal smears for detection of BV and leukocyte counts were obtained at speculum 
examinations. A large cotton-tipped swab, moistened with distilled water, was placed in 
the posterior fornix and swirled for 5 seconds. A thin smear of the secretion was applied 
to a dry slide and allowed to dry. The slides were processed by using Gram stain and read 
by LR (Study III) or a laboratory technician (Study IV). Both were blinded to any patient 
information at the time of reading. The presence of BV was determined on the basis of a 
Nugent Gram stain score of 7–10 (Nugent et al. 1991).
Leukocyte counts (IV)
Leukocytes counts from vaginal smears or dry slides were assessed in a semi-quantitative 
manner (0 = none, 1+ = few, 2++ = moderate, 3+++ = heavy). Groups 1–3 were markedly 
positive and 0 was markedly negative.  
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Statistical analysis
All data were analysed by using Microsoft’s Statistical Package for the Social Sciences 
(SPSS) for Windows, version 15.0 (I, II) and version 16.0 (III, IV and V). Because the 
phIGFBP-1 (I, II) and MMP-8 data (IV, V) did not follow normal distributions, not even 
after logarithmic transformation, nonparametric tests were used. A p-value less than 0.05 
was considered signifi cant. 
Study I 
Paired comparisons of continuous variables were carried out by using the Wilcoxon 
signed ranks test and unpaired comparisons with the Mann–Whitney test. Comparisons 
of categorial data were carried out by using the Chi-Square test and McNemar’s test when 
appropriate. Multivariate analysis of factors affecting cervical phIGFBP-1 concentrations 
(< 10 μg/l = 0, ≥ 10 μg/l = 1) was performed by multivariate logistic regression. All studied 
covariates were categorial and were entered in the model in one step. Adjusted ORs are 
given, with 95% confi dence intervals (95% CIs).
Study II 
Unpaired comparisons were analysed by using the Mann–Whitney test. Concentrations 
of phIGFBP-1 of ≥ 10μg/l and < 10 μg/l were categorial variables and compared by 
the χ² test, and Fisher’s exact test when appropriate. Logistic regression was used for 
multivariate analysis with parity, twin pregnancy, IVF, history of PTD, smoking, BMI, 
history of vaginal bleeding and phIGFBP-1 concentrations ≥10 μg/l as confounding factors 
for prediction of PTD at < 34 and < 37 weeks of gestation. It was also used to evaluate the 
possible contribution of previous vaginal bleeding and nulliparity, factors shown to affect 
cervical fl uid phIGFBP-1 concentrations. Receiver operating characteristic (ROC) curves 
were constructed to evaluate the diagnostic performance of cervical fl uid phIGFBP-1 
concentrations in prediction of PTD.  
Study III
Categorial variables were compared by Fisher’s exact test and continuous data with the 
Mann–Whitney test. Logistic regression was used for multivariate analysis (preterm birth 
at ≤ 34 weeks and delivery within 14 days as dependent factors, and cervical length, 
phIGFBP-1 test result and history of previous preterm birth as independent factors). 
Likelihood ratios for both outcomes were calculated for each factor.  
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Study IV
Paired comparisons of continuous variables were performed by using the Wilcoxon 
signed-ranks test and unpaired comparisons with the Mann–Whitney test (two groups) or 
the Kruskal–Wallis test (more than two groups). Correlations were calculated by using 
Spearman’s rank correlation coeffi cient test.  
Study V 
Unpaired comparisons of continuous variables were analysed by using the Mann–Whitney 
test. Categorial variables were compared by using the χ² test. Correlations between early 
and mid-pregnancy MMP-8 concentrations were examined by using Pearson’s correlation 
coeffi cient. Multiple logistic regression was carried out, with maternal age, parity, twin 
pregnancy, IVF, history of PTD, smoking, BMI > 30 kg/m², sexual intercourse < 48 hours 
earlier, history of vaginal bleeding during the current pregnancy and > the 90th percentile 
and < the median of MMP-8 concentrations taken into account to control for possible 
confounding factors and to calculate adjusted ORs and their 95% confi dence intervals for 
the risk of PTD initiated by PPROM < 37 weeks of gestation. 
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RESULTS
PhIGFBP-1 concentrations in the fi rst and mid-second trimester (I, II)
The characteristics of the study I population are shown in Table 7. Data concerning fi rst 
trimester sampling and mid-second trimester sampling were analysed separately in study 
I and II.
Table 7.  Characteristics of the Study I population
Participants 1690 1607
Drop outs 83 (4.9)
Maternal age, yrs 29.8 (4.6) 29.7 (4.6)
Parity
              Nullipara 912 (54.0) 874 (54.4)
                      Primigravida 687 (75.3) 657 (75.2)
                      Non-primigravida 225 (24.7) 217 (24.8)
               Multipara 778 (46.0) 733 (45.6)
Gestational age, wks 12.8 (0.6) 19.2 (0.8)
pH ? 4.7 164 (9.6) 110 (6.8)
Cervical length < 30 mm 11 (0.7) 6 (0.4)
History of sexual intercourse (<48h) 362 (21.4) 329 (20.1)
History of vaginal bleeding 147 (8.7) 38 (2.4)
History of use of antibiotics 101 (6.0) 83 (5.2)
Pregnancy
               Singleton  1673 (99.0) 1607 (100)
               Abnormal***  17 (1.0) 0
***Blighted ovum or fetal death
Numbers are n (%) or mean (SD)
          First trimester           Second trimester
First trimester samples 
PhIGFBP-1 was detected in 40.7% of the vaginal samples (I) and in 87.2% (I) and 69.9% 
(II) of the cervical samples (Table 8). The concentrations ranged from 0.3μg/l to 176.0μg/l 
(I) and from 0.3 μg/l to 174.0 μg/l respectively (I, II). Concentrations of phIGFBP-1 were 
signifi cantly higher in cervical than in vaginal samples (I) (p < 0.001) (Table 8). 
In the vaginal samples, the frequency of phIGFBP-1 concentrations of ≥ 10 μg/l was 5.8%. 
In the cervical samples, the corresponding rates were 34.3% (I) and 24.5% (II) (Table 8). 
Distributions and concentrations of phIGFBP-1 are shown in table 8 (I).                                                  
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Mid-second trimester samples
PhIGFBP-1 was detected in 34.8% of the vaginal samples. In cervical samples the 
corresponding rate wash 86.8% (I) (Table 8) and 70.6% (II). The concentrations ranged 
from 0.3μg/l to 55.0μg/l and from 0.3 μg/l to 126.0μg/l (I) and to 204.0μg/l respectively 
(II).  Concentrations of phIGFBP-1 were also signifi cantly higher in cervical than in vaginal 
samples (p < 0.001) (I) (Table 8). 
In the vaginal samples, the frequency of phIGFBP-1 concentrations of ≥ 10 μg/l was 1.5% 
(I). In the cervical samples, the corresponding rates were 28.3% (I) and 20.2% (II) (Table 
8). 
Table 8.  Distribution and concentrations of phIGFBP-1 in vaginal and cervical samples in 
the fi rst and the second trimesters of pregnancy 
phIGFBP-1 Undetectable > 0.3- 9.9 μg/l ? 10 μg/l Median (range)
                       n n (%) n (%) n (%) μg/l
First trimester
                   Vagina 1687 1001 (59.3) 588 (34.9)      98 (5.8)  <0.3  (<0.3-176)
                   Cx 1690  216 (12.8) 896 (53.0)      578 (34.2) 4.8  (<0.3-174)
Second trimester
                    Vagina 1606 1047 (65.2) 534 (33.3)       25 (1.5) <0.3   (<0.3-55)
                    Cx 1607  212 (13.2) 940 (58.5)       455 (28.3) 3.6 (<0.3-126)
Comparison of phIGFBP-1 in the fi rst and mid-second trimester 
The concentrations in both vaginal (I) and cervical samples (I, II) were higher in the fi rst 
trimester than in the mid-second trimester (vagina, p < 0.001, cervix, p < 0.001) (Table 8). 
Of the women with cervical phIGFBP-1 concentration of ≥ 10 μg/l in the fi rst trimester, 
54.9% had values of ≥ 10 μg/l in the mid-second trimester as well. In contrast, 85.5% of 
the women with cervical phIGFBP-1 concentration of < 10 μg/l in the fi rst trimester had a 
value of < 10 μg/l in the mid-second trimester sample as well (I). The corresponding rates 
in vaginal samples were 7.0% and 98.7%, respectively (I).
Factors affecting phIGFBP-1 concentrations (I, II, III)
 
First trimester samples
Of the factors studied in multivariate analyses, nulliparity (p < 0.001) and a history of 
vaginal bleeding (p < 0.001) were independently associated with cervical phIGFBP-1 
concentrations of ≥ 10 μg/l (I,II) (Table 9); nulliparity versus multiparity, OR 1.4, 95% CI 
1.1–1.7, and history of vaginal bleeding versus no bleeding, OR 2.5, 95% CI 1.7–3.5 (I). 
Similar associations were found in study II
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Among nulliparous women, those who had had previous pregnancies (miscarriage or 
termination of pregnancy), showed a higher rate of phIGFBP-1 concentrations of ≥10μg/l 
compared with nulliparous primigravid women (OR 1.5; 95% CI 1.1–1.2) (I). Sexual 
intercourse during the past 48 hours, or use of antibiotics within 4 weeks before sampling 
had no effect on either vaginal (I) or cervical phIGFBP-1 concentrations (I,II) (Table 9).
Mid-second trimester samples
Nulliparity and vaginal bleeding prior to sampling were signifi cantly associated with 
phIGFBP-1 concentrations ≥10μg/l both in univariate and multivariate analyses ( nulliparity 
versus multiparity, OR 3.2; 95% CI 2.3–5.5; vaginal bleeding vs. no bleeding OR 2.6; 95% 
CI 1.3–5.2) . The similar associations were found in study II. Sexual intercourse or use of 
antibiotics had no effect on either vaginal (I) or cervical phIGFBP-1 concentrations (I, II) 
(Table 9). 
Table 9.  Associations (p-values) between phIGFBP-1 concentrations of ≥ 10 μg/l and 
selected factors in vaginal and cervical samples
First trimester Second trimester
Patient characteristics Vagina (n=1687) Cervix (n=1690) Vagina (n= 1606) Cervix (n=1607)
Age, < 20 / 20-39 / > 40 years 0.023 Ns Ns Ns
Gestational age, < 12 / 12 to 14 / > 14 wks Ns Ns Ns Ns
Multiparity / nulliparity < 0.001 0.007 Ns <0.001
Vaginal pH ? 4,7 / < 4.7 0.047 Ns Ns Ns
Cervical length , < 30 mm / ? 30 mm Ns Ns Ns Ns
History of sexual intercourse (<48h) Ns Ns Ns Ns
History of vaginal bleeding < 0.001 < 0.001 < 0.001 0.003
History of use of antibiotics Ns Ns Ns Ns
Late-second trimester and third trimester samples (III)
Vaginal bleeding during the current pregnancy was signifi cantly associated with a positive 
phIGFBP-1 test result (p = 0.003). Bacterial vaginosis, subsequent puerperal infection and 
sexual intercourse within 48 hours had no association with phIGFBP-1 test results. 
Association of phIGFBP-1 with PTD (II)
In the fi rst trimester study population the rates of spontaneous PTD at < 32 and < 37 weeks 
of gestation were 0.5% and 3.8%, respectively. In the second trimester study population 
the corresponding rates were 0.5 % and 3.6 %, respectively. Characteristics and obstetric 
outcomes of the study populations are shown in Table 10. 
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Table 10.  Characteristics and obstetric outcomes of study populations in the fi rst and 
second trimesters
< 32 weeks ? 32 weeks < 37 weeks ? 37 weeks < 32 weeks ? 32 weeks < 37 weeks ? 37 weeks
n 26 4958 189 4795 21 4609 167 4463
Maternal age (years) 31.4 ( 4.9) 30.0 (4.5) 29.8 (4.8) 30.1 (4.5) 30.7 (5.0) 30 (4.5) 29.8 (4.8) 30.0 (4.6)
Nulliparity, % 42.3 49.3 55.0 49.0 42.9 49.6 55.7 49.3
Twin pregnancy,% 3.8 0.6* 6.3 0.4* 4.8 0.6* 6.6 0.4*
History of preterm delivery,% 19.2 3.1* 10.1 2.9* 19.0 3.1* 10.2 2.9*
IVF,% 7.7 3.3 6.3 3.2* 4.8 3.3 6.6 3.1*
Smoking,% 20.8 11.2 21.0 10.9* 26.3 11.1* 21.7 10.7*
History of vaginal bleeding during 23.1 9.4* 17.6 9.1* 35.0 11.7* 20.9 11.4*
BMI kg/m² 23.2 (5.2) 23.5 (4.1) 23.7 (4.8) 24.5 (4.1) 24.6 (4.3) 23.5 (4.2) 23.8 (4.2) 23.5 (4.8)
BMI > 30 kg/m², % 17.4 7.1 8.8 7.1 11.1 7.4 8.6 7.3
Gestational age at examination 12.9 (0.6) 12.8 (0.7) 12.7 (0.9) 12.8 (0.7) 19.3 (0.4) 19.3 (0.7) 19.2 (0.9) 19.3 (0.9)
Gestational age at delivery (weeks) 27.9 (3.0)  40.1 (1.4)* 34.5 (3.0) 40.3 (1.2)* 24.6 (3.1) 40.1 (3.1)* 35.6 (3.0) 40.2 (1.9)*
Birth weight (g) 1196 (649) 3564 (429)* 2575 (727) 3575 (464)* 1100 (692) 3563 (491)* 2472 (700) 3591 (464)*
Mean (SD) or %
* p< 0.05 
First trimester Second trimester
First trimester samples
The median phIGFBP-1 concentration was higher in women with spontaneous delivery at 
< 32 weeks of gestation compared with women who delivered at > 32 weeks (12.0 vs. 2.5 
μg/l, p = 0.004). The median phIGFBP-1 concentration in women who delivered at < 37 
weeks of gestation was also higher compared with women who had term delivery (3.7 vs. 
2.5μg/l, p <0.001). 
The rates of spontaneous PTD at < 32 weeks and < 37 weeks of gestation were higher in 
women with elevated (≥10μg/l) cervical fl uid phIGFBP-1 compared with women who had 
cervical phIGFBP-1 levels of < 10 μg/l (1.1% vs. 0.3%; p < 0.001 and 5.7% vs. 3.2%; p < 
0.001, respectively). 
 
Elevated cervical fl uid phIGFBP-1 levels in the fi rst trimester increased the risk of 
subsequent spontaneous PTD at < 32 weeks of gestation (OR 3.6; 95% CI 1.7–7.9) and at 
< 37 weeks of gestation (OR 1.9; 95% CI 1.3–2.5). Multiple logistic regression analysis 
confi rmed that, even when other risk factors were accounted for, an elevated level of 
cervical fl uid phIGFBP-1 was an independent predictor of PTD at < 32 weeks of gestation, 
with an OR of 3.0 (95% CI 1.3–7.0) and at < 37 weeks of gestation, with an OR of 1.6 (95% 
CI 1.2–2.3) (Table 11). 
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Table 11.  Multivariate analysis of risk factors of preterm delivery at < 32 weeks’ gestation 
and < 37 weeks’ gestation in the fi rst trimester and second trimester (II)
 < 32 weeks < 37 weeks < 32 weeks (n=21) < 37 weeks 
Nulliparity 1.1  (0.4-2.9) 1.6  (1.1-2.2) 1.5 (0.5-4.7) 1.6 (1.1-2.4)
Twin  7.1  (0.9-59.1) 13.5 (6.0-30.3)  13.6 (1.6-115.2) 18.9 (8.2-43.6)
IVF 1.6  (0.3-7.9) 1.5  (0.8-3.0)  1.3 (0.2-10.9) 1.6 (0.8-3.2)
History of preterm delivery   7.6  (2.4-24.1) 4.7 (2.6-8.3) 10.5 (2.7-40.7) 5.2 (2.8-9.3)
Smoking 2.2  (0.8-5.9) 2.0 (1.4-3.0) 3.1 (1.1-9.1) 2.2 (1.5-3.4)
BMI > 30 kg/m² 2.6  (0.8-7.8) 1.2 (0.7-2.1) 1.7 (0.4-7.6) 1.1 (0.6-2.0)
History of vaginal bleeding 2.7  (1.0-7.3) 2.1  (1.4-3.1) 5.2 (1.9-14.1) 2.0 (1.3-3.1)
Cervical phIGFBP-1 ? 10 micrograms/l 3.0  (1.3-7.0) 1.6  (1.2-2.3) 1.9 (0.7-5.3) 1.4 (1.0-2.1)
Adjusted OR (95% CI)
            First trimester Second trimester
The ROC curve illustrating the accuracy of cervical fl uid phIGFBP-1 is shown in Figure 11 
A. The area under the curve (AUC) as regards predicting spontaneous PTD at < 32 weeks 
was 0.66 (95% CI 0.55–0.76) and at < 37 weeks of gestation, 0.59 (0.54–0.63). A cut-off 
value of 10μg/l predicted PTD at < 32 and < 37 weeks of gestation with sensitivities of 
53.8% and 37.0%, and false-positive rates of 24.3% and 24.0%, respectively. Negative 
predictive values were 99.7% and 96.8%, respectively. 
Figure 11.  ROC curves of cervical fl uid phIGFBP-1 levels in the fi rst (A) and second (B) 
trimesters for predicting preterm delivery before 32 weeks of gestation. The sensitivity and 
100-specifi city points for phIGFBP-1 values of 5, 10 and 20 μg/l are marked
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Mid-second trimester samples
The median phIGFBP-1 concentration was higher in women with spontaneous delivery 
at < 32 weeks of gestation compared with women who delivered at ≥ 32 weeks (7.5 vs. 
2.1 μg/l, p = 0.003). No difference was found in cervical fl uid phIGFBP-1 concentrations 
between women with PTD at < 37 weeks of gestation and those with term delivery (2.5 vs. 
2.1 μg/l, p = 0.059). 
The rates of spontaneous PTD at < 32 weeks and at < 37 weeks of gestation were higher in 
women with elevated cervical fl uid phIGFBP-1 concentrations compared with women who 
had cervical fl uid phIGFBP-1 levels of < 10 μg/l (0.9% vs.0.4%; p = 0.041 and 5.1% vs. 
3.2%; p = 0.005, respectively). 
An elevated cervical fl uid phIGFBP-1 level increased the risk of subsequent spontaneous 
PTD at < 32 and <37 weeks of gestation (OR 2.4; 95% CI 1. 0–5.9 and OR of 1.6; 95% 
CI 1.2–2.3). In multiple logistic regression analysis an elevated cervical fl uid phIGFBP-1 
level was not an independent predictor of PTD (Table 11).
The ROC curves illustrating the accuracy of cervical fl uid phIGFBP-1 concentrations are 
shown in Figure 11 B. The AUC (95% CI) as regards the prediction of spontaneous PTD 
at < 32 weeks was 0.68 (0.56–0.80) and at < 37 weeks of gestation, 0.54 (0.50–0.59). A 
cervical fl uid phIGFBP- 1 concentration of ≥ 10 μg/l predicted subsequent spontaneous 
PTD at < 32 and < 37 weeks of gestation with sensitivities of 38.1% and 28.7%, and with 
false-positive rates of 20.1% and 19.9%, respectively. Negative predictive values were 
99.6% and 96.8%, respectively. 
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PhIGFBP-1 strip test and cervical length measurement in prediction of PTD (III)
The overall rate of spontaneous PTD at ≤ 34 weeks of gestation was 4.1% (10/246). Seven 
of ten cases (70.0%) occurred within 14 days of examination. Of the studied historical 
risk factors, a history of previous PTD in parous women, and puerperal infection were 
associated with PTD at ≤ 34 weeks of gestation (p = 0.003 and p = 0.037, respectively) 
(Table 12).
Table 12.  Demographic and clinical characteristics and obstetric outcomes of the study 
population in Study III
Delivery 
? 34 weeks
Delivery 
> 34 weeks
n = 10 n = 236 
Maternal age, years 29.1 (21-36) 29.9 (18-40)
Parity
         Nullipara 6 (60.0) 97 (41.1)
         Multipara 4 (40.0) 139 (58.9)
History of preterm birth 3 (75.0) 11 (7.9) *
Gestational age at examination, weeks 28.2 (25.4-32.8) 28.1 (22.0-34.0)
BMI before pregnancy                    21.6 (18-38) 22.4 (17-47)
Smoking
         Yes  1 (10.0) 5 (2.1)
         Stop 1. trimester 2 (20.0) 27 (11.6)
         No 7 (70.0) 201 (86.3)
Sexual intercourse within 48 hours 3/7 (42.9) 34/179 (19.0)
Bacterial vaginosis 0 (0.0) 7 (3.0)
Chlamydia trachomatis 0 (0.0) 0 (0.0)
Streptococcus agalactiae 1/7 (14.2) 35/142 (24.6)
Previous vaginal bleeding 2 (20.0) 34 (14.4)
Hospital admission 7 (70.0) 11 (4.7) *
Use of tocolysis 9 (90.0) 14 (5.9) *
Use of corticosteroids 8 (80.0) 11 (4.7) *
Gestational age at delivery, weeks 31.9 (27.1-33.8) 39.8 (35.0-42.4) *    
Puerperal infection** 2 (20.0) 6 (2.5) *
Time from examination to delivery, weeks 1.2 (0- 8.4) 11.7 (2.8-19.8) *
Birth weight, g 1790 (1000-2355) 3484 (1930-4830) *
Note : Data expressed as n (%) or median
* p< 0.05
** Puerperal infections: one sepsis,one infection after cesarean section, three amnionitis, three endometritis
A short cervix was found in 7.3% (18/246) of the patients, with funnelling in four of them 
(22.0%). Rapid phIGFBP-1 test result was positive in 14.6% (36/246) of the patients. The 
median gestational age as regards both positive and negative phIGFBP-1 results was 28.1 
weeks (range 22.0–33.7 weeks and 22.1–34.0 weeks, respectively). The frequency of a 
positive phIGFBP-1 test result was 22.2% (4/18) among patients with a cervical length of 
< 25 mm, and 14.0 % (32/228) among patients with a cervical length of > 25 mm. Using 
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this cut-off, the agreement between cervical length and cervical phIGFBP-1 test results was 
poor (kappa = 0.056).  
 
Eighteen women were admitted on the basis of the physician’s judgment, including 
knowledge of cervical changes. Eight of the admitted patients had a short cervix and six had 
a positive phIGFBP-1 test result. Tocolytic treatment was given to 16 of the 18 hospitalized 
patients and to 7 of the 228 discharged women. 
A short cervix (p = 0.003) and a positive phIGFBP-1 test result (p = 0.007) were both 
associated with PTD at ≤ 34 weeks or within 14 days (p < 0.001) (Table 13). The relevance of 
a short cervix, a positive phIGFBP-1 test result, their combination, and the likelihood ratios 
(LRs) for spontaneous PTD at ≤ 34 weeks of gestation and within 14 days of examination 
are shown in Table 14. In multiple regression analysis, short cervical length (OR 8.6; 95% 
CI 2.2–33.4) and a positive phIGFBP-1 test result (OR 6.6; 95% CI 1.8–24.2) remained 
signifi cant independent predictors of PTD at ≤ 34 weeks and within 14 days of examination 
(OR 9.4; 95% CI 1.9-46.9 and OR 9.2; 95% CI 1.9-44.4, respectively).
Table 13.  Rate of spontaneous PTD (less than 34 weeks or within 14 days) among 246 
women reporting uterine contractions in relation to cervical length and cervical phIGFBP-1 
results (Study III)
Examination Rate
Delivery 
? 34 weeks
Delivery
> 34 weeks P -value
Delivery   
? 14 days
Delivery   
> 14 days P -value
n 10 236 7 239
Cervical length p=0.003 p=0.001
     < 25 mm 18 (7.3) 4 (22.2) 14 (77.8) 4 (22.2) 14 (77.8)
     ? 25 mm 228 (92.7) 6 (2.6) 222 (97.4) 3 (1.3) 225 (98.7)
phIGFBP-1-test p=0.007 p=0.001
     Positive 36 (14.6) 5 (13.9) 31 (86.1) 5 (13.9) 31 (86.1)
     Negative 210 (85.4) 5 (2.4) 205 (97.6) 2 (1.0) 208 (99.0)
Data expressed as n (%)
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Table 14.  Test performance of short cervix, phIGFBP-1 or their combination, and clinician’s 
judgment with likelihood ratios (LRs) of spontaneous preterm delivery at less than 34 
weeks’ gestation and within 14 days of examination
n Sensitivity (%) Specificity (%) PPV (%) NPV (%) LR+ LR-
Delivery at ?  34 weeks 10
Cervix < 25mm 4 40.0 94.1 22.2 97.4 6.8 0.6
phIGFBP-1 + 5 50.0 86.9 13.9 97.6 3.8 0.6
Cervix < 25 mm and phIGFBP-1 + 3 30.0 99.6 75.0 97.1 75.0 0.7
Cervix < 25 mm or phIGFBP-1 + 6 60.0 81.4 12.0 98.0 3.2 0.5
Delivery within 14 days 7
Cervix < 25mm 4 57.1 94.1 22.2 98.7 9.7 0.5
phIGFBP-1 + 5 71.4 87.0 13.9 99.0 5.5 0.3
Cervix < 25 mm and phIGFBP-1 + 3 42.9 99.6 75.0 98.3 107.3 0.6
Cervix < 25 mm or phIGFBP-1 + 6 85.7 81.6 12.0 98.0 4.7 0.2
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MMP-8 concentrations in fi rst and mid-second trimester (IV, V)
Characteristics of the study population IV are shown in Table 15. MMP-8 was detectable in 
almost 100% of vaginal (IV) and cervical swab samples (IV,V)  in the fi rst and mid-second 
trimesters. The concentrations ranged from 0.08μg/l to about 2000 μg/l (Table 16 and 19). 
The overall ranges of cervical fl uid MMP-8 concentrations and median values were similar 
in the fi rst trimester and in the second trimester (IV,V). Signifi cant correlations were found 
between fi rst and second trimester vaginal samples (r = 0.67, p < 0.01) and between fi rst 
and second trimester cervical samples (r = 0.54, p < 0. 01) (IV).
Table 15.  Characteristics of the study populations (Study IV)
Total 1979 1950
Pregnancy, n (%)
Singleton 1944 (98.2) 1932 (99.1)
Twin 18 (0.9) 18 (0.9)
Abnormal* 17 (0.9)
Miscarriage between 12 (0.6)
Parity
                       Nullipara 1055 (53.3) 1041 (53.4)
                                  Primigravida 799 (75.7) 787 (75.6)
                                  Non-primigravida 256 (24.3) 254 (24.4)
                       Multipara 924 (46.7) 909 (46.6)
History of vaginal bleeding 177 (8.9) 47 (2.4)
History of sexual intercourse (<48h) 452 (22.8) 422 (21.7)
History of use of antibiotics 117 (5.9) 104 (5.3)
Vaginal Gram-stain findings**
                       Bacterial vaginosis 81 (4.1) 76 (3.8)
                       Leukocytes in vagina 598 (30.5) 550 (28.4)
1+ 542 (27.7) 448 (23.1)
2+ 54 (2.8) 87 (4.5)
    3+++ 2 (0.1) 15 (0.8)
                      Candidiasis 62 (3.1) 37 (1.9)
Cervical length < 30 mm 5 (0.3) 6 (0.3)
*   Blighted ovum or fetal death
** Missing values: 20 in the first trimester, 13 in the second trimester
   First trimester    Second trimester
n (%) n (%)
First trimester samples
Median MMP-8 concentrations were signifi cantly higher in cervical than in vaginal samples 
in the fi rst trimester (p < 0.001) (Table 16). Signifi cant correlations were found between 
vaginal and cervical MMP-8 concentrations (r = 0.54, p < 0. 01). 
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Table 16.  MMP-8 concentrations in vaginal and cervical samples (Study IV)
Vagina Cervix Vagina Cervix
Median 107.4 318.3 112.5 344.8
Range <0.08° - 2406.6 0.1 - 2074.6 <0.08°° - 2093.4 0.4 - 1783.5
Percentiles
10    3.1   47.2  4.6  55.2
25   16.4 118.3 23.5 132.2
50 107.4 318.3 112.5 344.8
75 379.6 620.0 416.2 657.5
90 762.0 901.7 842.1 918.2
 °Four
°°One
    First trimester (n = 1979)     Second trimester (n=1950)
MMP-8 (µg/l) MMP-8 (µg/l)
Second trimester samples
Median MMP-8 concentrations were signifi cantly higher in cervical than in vaginal samples 
in the (IV,V)(p < 0.001) (Table 16). Signifi cant correlations were found between vaginal 
and cervical MMP-8 concentrations (r = 0.53, p < 0.01).
Factors affecting MMP-8 concentrations
 
Associations between selected factors and MMP-8 concentrations in vaginal and cervical 
samples are shown in Table 17.
First trimester samples
Multiparity, bacterial vaginosis, and vaginal leukocytosis were associated with increased 
MMP-8 concentrations in vaginal and cervical samples. Vaginal and cervical fl uid MMP-
8 concentrations were signifi cantly higher in women who had both BV and an increased 
number of vaginal leukocytes than in women with either BV or an increased number of 
vaginal leukocytes, or negative fi ndings (IV). Sexual intercourse within the previous 48 
hours was associated with lower cervical fl uid MMP-8 concentrations (IV,V). BMI ≥ 30 
kg/m² was associated with MMP-8 concentrations greater than the 90th percentile with OR 
1.6; 95% CI 1.2–2.2 (V).
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Second trimester
Multiparity and vaginal leukocytosis were associated with increased MMP-8 concentrations 
in vaginal and cervical samples. Bacterial vaginosis was associated with increased vaginal 
MMP-8 but not with cervical MMP-8. Vaginal and cervical fl uid MMP-8 concentrations 
were signifi cantly higher in women who had both BV and an increased number of vaginal 
leukocytes than in women with either BV or an increased number of vaginal leukocytes, or 
negative fi ndings (IV). Sexual intercourse was associated with lower cervical fl uid MMP-8 
concentrations as in fi rst trimesters (IV,V). BMI ≥ 30 kg/m² was associated with increased 
MMP-8 concentrations with OR 1.9; 95% CI 1.4–2.6) (V).
Table 17.  Associations (p-values) between MMP-8 concentrations and selected factors in 
vaginal and cervical samples in the fi rst and second trimesters
Selected factor
MMP-8 (µg/l) Vagina Cervix Vagina Cervix
n 1979 1950
Age, < <20 / 20-39 / >40 years Ns Ns Ns Ns
Gestational age, < 12 / 12 to 14 / > 14 wks Ns Ns Ns Ns
Gravidity, nulligravida/ nullipara multigravi Ns Ns Ns 0.051
Multiparity / nulliparity <0.001 <0.001 <0.001 <0.001
Bacterial vaginosis <0.001 <0.001 <0.001 Ns
Vaginal leukocytosis 0.001 0.001 <0.001 0.008
Vaginal candidiasis Ns Ns Ns Ns
Cervical length , < 30 mm / ? 30 mm Ns Ns Ns Ns
History of sexual intercourse (<48h) Ns <0.001 0.004 <0.001
History of vaginal bleeding Ns 0.037 Ns Ns
History of use of antibiotics Ns Ns Ns Ns
Type of pregnancy
Single / Twin Ns Ns Ns Ns
Normal / Abnormal *** Ns Ns Ns Ns
*** Blighted ovum or fetal death
First trimester Second trimester
Association of cervical fl uid MMP-8 with PTD (V)
Demographic and clinical characteristics of the fi rst and second trimester study populations 
are shown in Table 18. The mean gestational age at examination was 12.8 weeks in the fi rst 
trimester and 19.3 weeks in the second trimester. The overall rate of spontaneous PTD at < 
37 weeks of gestation was 3.8%. The mean gestational age among preterm deliveries was 
34.6 weeks (range 22.8 to 36.8), and in the term delivery cohort it was 40.3 weeks (range 
37.0 to 42.8).
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Table 18.  Characteristics of the fi rst and second trimester study populations in relation to 
the time of delivery
n= 184  n = 4671 n= 164 n = 4407
Age ? 37 years 14 (7.6) 379 (8.1) 11 (6.7) 342 (7.8)
Multipara 84 (45.7) 2395 (51.3) 73 (44.5) 2241 (50.9)
Twin pregnancy 12 (6.5) 19 (0.4) * 11 (6.7) 16 (0.4) *
History of preterm delivery 19 (10.3) 138 (3.0) * 16 (9.8) 127 (2.9) *
IVF 12 (6.5) 153 (3.3) * 11 (6.7) 140 (3.2) *
Smoking 36 (21.1) 484 (11.0) * 34 (22.1) 446 (10.7) *
BMI > 30 kg/m² 15 (9.1) 317 (7.2) 13 (8.8) 307 (7.4)
Sexual intercourse < 48h 38 (20.8) 981 (21.0) 32 (20.0) 811 (18.6)
History of vaginal bleeding 32 (17.6) 422 (9.1) * 13 (8.1) 146 (3.4) *
* p < 0.05
n (%)
> 37 wks
Second  trimesterFirst trimester
< 37 wks > 37 wks < 37 wks
There was no difference in median MMP-8 concentrations between women with 
spontaneous PTD (< 37) and at term delivery (> 37 weeks of gestation) (Table 19). Cervical 
fl uid MMP-8 concentrations in women with spontaneous PTD preceded by PPROM and in 
those with PTD initiated by spontaneous labour were also assessed in relation to MMP-8 
concentrations in women with term delivery (Figure 12). No differences were detected in 
median MMP-8 concentrations, in either the fi rst or in the second trimester, between the 
women who had PTD after spontaneous onset of labour versus those with spontaneous 
delivery at term. Cervical fl uid MMP-8 concentrations were lower among women with 
subsequent PPROM at < 37 weeks of gestation compared with those with subsequent term 
delivery and those with PTD initiated with preterm contractions with intact membranes, the 
differences being signifi cant in the second trimester only (p = 0.016 and 0.023, respectively) 
(Table 19).
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Figure 12. A and B Boxplots of cervical fl uid MMP-8 concentrations in women with term 
delivery and in preterm subgroups (preterm labour and PPROM) in the fi rst (A) and second 
(B) trimesters.
Table 19. Cervical fl uid MMP-8 concentrations in women with spontaneous preterm delivery 
and term delivery
   MMP-8 (µg/l)                          Spontaneous preterm delivery Term delivery p-value
Total Preterm labour PPROM Total
First trimester (No) 184 116 68 4671
   Median (range) 233.6 (< 0.08-1708.6)* 258.6 (< 0.08- 1708.6)° 183.2 (0.2- 1341.0)°° 258.9 (< 0.08-2197.5) 0.849*
   (10th-90th percentile) (13.9-923.6) (11.5-1079.0) (17.2-817.9) (11.3-915.2)
Second trimester (No) 164 101 63 4407
   Median (range) 185.6 (< 0.08-1750.9)* 231.7 (0.4-1750.9)° 119.4 (< 0.08-1169.9)°° 268.0 (< 0.08-1973.3) 0.357*
   (10th-90th percentile) (11.0-1050.5) (14.1-1156.0) (4.0-738.5) (9.9-918.0)
* Spontaneous preterm delivery vs.term delivery
° Preterm labour vs. term delivery (p=0.497 in the first trimester; p=0.418 in the second trimester)
°° PPROM vs. term delivery (p=0.227 in the first trimester; p=0.016 in the second trimester)
For further analysis, the MMP-8 concentrations were dichotomized, and the 90th percentile 
value among cases ending with term delivery was used as the upper limit of normal. Among 
the women with PTD initiated by spontaneous labour, 16.9% had cervical fl uid MPP-8 
concentrations greater than the 90th percentile (≥ 918. 0 μg/l) among term controls in the 
mid-second trimester (OR 1.8, 95% CI 1.1–3.1). This cut-off level showed a sensitivity of 
16.8% and a specifi city of 90.0%. After adjusting for maternal age, parity, twin pregnancy, 
history of PTD, IVF, smoking, body mass index, sexual intercourse in the previous 48 
hours and previous vaginal bleeding, MMP-8 concentration in the second trimester greater 
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than this 90th percentile value remained as an independent factor associated with PTD 
initiated by spontaneous labour (OR 2.0; 95% CI 1.1–3.5) (Table 20)
Table 20.  Multivariate analysis of risk factors of preterm delivery at < 37 weeks’ of gestation 
among women with subsequent preterm labour 
Maternal age, >37  years 0.9 (0.4-1.8) 0.8 (0.3-1.8)
Multipara 0.6 (0.4-0.9) 0.6 (0.3-0.9)
Twin pregnancy 14.6 (5.4-39.6) 17.4 (6.3-48.2)
History of preterm delivery 6.9 (3.6-13.3) 6.6 (3.2-13.6)
IVF 1.8 (0.9-3.9) 1.9 (0.8-4.5)
Smoking 2.0 (1.2-3.3) 2.5 (1.5-4.2)
BMI ? 30 kg/m² 1.8 (1.0-3.3) 1.4 (0.7-2.8)
Sexual intercourse (< 48hours) 1.0 (0.6-1.6) 0.7 (0.4-1.3)
History of vaginal bleeding 3.1 (1.9-5.1) 2.7 (1.2-6.1)
Cervical fluid MMP-8 > 90 percentile* 1.3 (0.7-2.3) 2.0 (1.1-3.5)
*  MMP-8 concentration (90 percentile in term controls 915.2 μg/l in the first trimester 
and 918.0 μg/l in the second trimester)
Second trimester   
Adjusted OR (95% CI)
First trimester    
Of the women with subsequent PPROM at < 37 weeks of gestation, 66.7% had cervical 
fl uid MPP-8 concentrations under the median (268.0 μg/l) of term controls in the second 
trimester. MMP-8 concentrations below the median were associated with an increased risk 
of PPROM, with an OR of 2.0 (95% CI 1.2–3.4).
However, after adjusting for affected factors cervical fl uid MMP-8 concentrations under 
the median value remained associated with subsequent PPROM (OR 2.0; 95% CI 1.1–3.2) 
in the second trimester, but not in the fi rst trimester (OR 1.3; 95% CI 0.7-2.7) (Table 21).
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Table 21. Multivariate analysis of risk factors of preterm delivery at < 37 weeks’ of gestation 
among women with subsequent PPROM
Maternal age,  >37  years 1.0 (0.4-2.6) 0.6 (0.2-2.0)
Multipara 0.7 (0.4-1.3) 0.7 (0.4-1.3)
Twin pregnancy 18.0 (5.7-57.0) 22.6 (6.9-73.5)
History of preterm delivery 2.1 (0.6-7.2) 2.6 (0.7-9.0)
IVF 1.0 (0.3-3.6) 1.3 (0.4-4.5)
Smoking 1.9 (1.0-3.6) 1.9 (1.0-3.8)
BMI ? 30 kg/m² 0.4 (0.1-1.7) 0.5 (0.1-1.9)
Sexual intercourse (< 48hours) 0.5 (0.3-1.1) 1.6 (0.9-2.8)
History of vaginal bleeding 0.9 (0.4-2.4) 3.3 (1.3-8.6)
Cervical fluid MMP-8 < median * 1.3 (0.7-2.2) 2.0 (1.1-3.7)
* MMP-8 concentration (median 258.9 μg/l in first trimester and 268.0 μg/l in second trimester)
Adjusted OR (95% CI)
First trimester Second trimester
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DISCUSSION
Worldwide preterm delivery(PTD) complicates about 3% of pregnancies before 34 weeks 
of gestation and 5% - 15 % before 37 weeks of gestation (Goldenberg et al. 2008, Slattery 
and Morrison 2002). In Finland the incedence of PTD has staied stabile and is about 5-6% 
(Jakobsson et al 2008) while it has increased in alsewere in the world (Goldenberg et al. 
2008, Muglia et al. 2010). Two thirds of PTD occur spontaneously. In our study, spontaneous 
PTD rate < 32 weeks of gestation was 0.5% and < 37 weeks of gestation 3.8%. Prematurity 
is still a major cause of perinatal morbidity and mortality and has serious effects on society, 
making PTD an important issue to public health worldwide. Therefore, prediction and 
prevention of PTD remains a big challenge in obstetrics. If a woman could be identifi ed 
to be at high risk for PTD in early pregnancy, she could be targeted for more intensive 
antenatal surveillance and prophylactic interventions. Furthermore, when a woman presents 
with symptoms of threatened PTD and, the likelihood of having a spontaneous PTD can 
be determined, interventions can be developed to prevent or delay delivery, and to improve 
subsequent neonatal mortality/morbidity. 
Many biomarkers, including phosphorylated insulin-like growth factor binding protein-1 
(phIGFBP-1) and matrix metalloproteinase-8 (MMP-8), have recently been evaluated for 
prediction of PTD among symptomatic women but so far none of them has appeared to be 
superior in clinical practice (Honest et al. 2009), and their performance among asymptomatic 
women in early pregnancy has remained unclear. Before our study the knowledge of the 
presence, concentrations, and factors associating with phIGFBP-1 and MMP-8 in the lower 
genital tract in early- and mid-gestation was limited (Honkanen et al. 2004, Kekki et al. 
1999).
The main purpose of this study was to evaluate whether phIGFBP-1 and MMP-8, as 
measured in lower genital tract fl uids in early and mid-second pregnancy are associated 
with subsequent PTD, and whether they can predict this detrimental event in asymptomatic 
women.
We fi rst measured the concentrations of phIGFBP-1 and MMP-8 in cervical fl uids and 
examined factors infl uencing the concentrations in early and mid-pregnancy. Secondly, 
associations between elevated cervical fl uid phIGFBP-1 and spontaneous PTD < 32 weeks 
of gestation and < 37 weeks of gestation as well as the associations between cervical fl uid 
MMP-8 and PTD < 37 weeks of gestation were analyzed. Thirdly, the performance of the 
rapid phIGFBP-1 strip test in prediction of PTD among women with self-reported uterine 
contractions during the second half of pregnancy was evaluated.
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Concentrations of phIGFBP-1 in the lower genital tract in the fi rst and mid- second 
trimester (I, II)
IGFBP-1 is produced by human decidua, in which the phosphorylated isoforms, phIGFBP-1, 
predominate (Giudice and Irwin 1999, Westwood et al. 1994). These are the fi rst reports 
(I, II) on phIGFBP-1 concentrations in vaginal and cervical secretions of unselected, 
asymptomatic pregnant women during the fi rst and mid-second trimester. Mechanism(s) 
accounting for the absence and presence of phIGFBP-1 in the lower genital tract fl uid 
in early pregnancy have not been well defi ned. The most likely explanation is that small 
amounts of chorionic/decidual products leak into the cervical canal before the fusion of 
capsular and parietal decidua. This supposed to be completed during the early second 
trimester (Lockwood et al 1991). 
Although the range of phIGFBP-1 concentrations, as measured by immunoenzymometric 
assay, was roughly similar in the vaginal and cervical samples in the fi rst and mid-second 
trimester, the protein was detectable in cervical samples more than twice as often as in the 
vaginal samples in both trimesters, and the median concentrations were signifi cantly higher 
in cervical samples than in vaginal samples. Thus, our data clearly show that the site of 
sampling has to be defi ned and considered when phIGFBP-1 is used as decidual marker, 
and data interpreted for research or clinical purposes.  For comparison, the diagnosis of 
ruptured fetal membranes was based on the detection of amniotic fl uid isoforms of IGFBP-1 
in vaginal swab samples (Actim PROM test; Medix Biochemica).
In Studies I and II, we used the same cut-off level for elevated phIGFBP-1 (≥ 10 μg/l) 
as used previously by us (Kekki et al. 1999, Kekki et al. 2001, Nuutila et al. 1999) and 
an other study (Paternoster et al. 2007) to enable comparisons between early and late 
pregnancy. This is also the detection limit of the rapid strip test for phIGFBP-1 (Actim 
Partus test, Medix Biochemica) that has been used in many recent studies for prediction of 
spontaneous PTD (Kwek et al. 2004, Lembet et al. 2002, Paternoster et al. 2009, Tanir et 
al. 2009, Ting et al. 2007).  However, in some studies a strong positive rapid phIGFP-1 test 
result has been interpreted to be equal to 30 μg/l instead 10 μg/l (Altinkaya et al. 2009, Brik 
et al. 2010, Elizur et al. 2005). 
In study I, the rate of the phIGFBP-1 values ≥10 μg/l was about six times higher in the 
cervical samples than in the vaginal samples in the fi rst trimester, and during the second 
trimester the ratio was 18. The instability in vaginal fl uid phIGFBP-1 concentrations let us 
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to use cervical samples in later studies (II, III). In Study I, one third of women and in study 
II one fourth of women had an elevated cervical fl uid phIGFBP-1 level in the fi rst trimester. 
In the second trimester, the rates were one fourth to one fi fth, respectively. The high rate 
of phIGFBP-1 values above this cut-off in cervical samples among asymptomatic pregnant 
women suggests that a concentration ≥10 μg/l in cervical fl uid may also be physiological 
during the fi rst half of pregnancy. 
Factors affecting phIGFBP-1 concentrations in the lower genital tract in the fi rst 
and mid-second trimester (I II)
In study I, only half of the women who had cervical phIGFBP-1 level ≥ 10μg/l in the 
fi rst trimester had the same result in the second trimester, whereas most (85.6%) of the 
women with cervical phIGFBP-1 < 10μg/l in the fi rst trimester showed no change in the 
second trimester. These data are in line with the hypothesis that the disappearance of 
phIGFBP-1 from the lower genital tract occurs concurrently with the fusion of capsular and 
parietal decidua. The change from the level < 10μg/l to ≥ 10μg/l between the fi rst and the 
second trimester in 14.5% of women requires another explanation. One possibility could 
be subclinical ascending infection and tissue disruption at the choriodecidual interface 
between the fi rst and second sampling. In support of this, a previous study by Kekki et 
al (1999) showed that women with BV in early pregnancy concurrently with a cervical 
fl uid phIGFBP-1 ≥ 10μg/l had s signifi cantly increased risk of peripartum infections as 
compared to women with BV and phIGFBP-1 < 10μg/l (Kekki et al. 1999). The similar 
association between BV and elevated FFN has been described by Goldenberg (Goldenberg 
et al. 2000). Unfortunately we did not have data on BV in Study I and II. 
It has been shown previously that IGFBP-1 concentration in seminal plasma varies from 
undetectable to very low (Rutanen et al. 1993), suggesting that phIGFBP-1 could be used as 
a decidual marker even after sexual intercourse. However, the effect of sexual intercourse 
itself on phIGFBP-1 in the lower genital has not been reported previously. In our study 
I and study II, one fi fth of women expressed having had sexual intercourse during the 
last 48 h before sampling. Sexual intercourse appeared to have no effect on cervical fl uid 
phIGFBP-1 concentrations, confi rming that phIGFBP-1-measurement in the lower genital 
tract remains reliable even after intercourse. In comparison, the FFN test result may be 
affected seminal plasma, and is not useful if the woman has had sexual intercourse during 
24 hours (Shimoya et al. 1998, Honest et al. 2002).
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In Study I and II we show that history of vaginal bleeding in current pregnancy is associated 
with elevated cervical fl uid phIGFBP-1. An occult bleeding might account for this 
association, since the same phosphoisoforms of IGFBP-1 predominate in the decidua and 
in the maternal serum (Martina et al. 1997). Another possibility is that previous decidual 
haemorrhage may have caused an injury at the choriodecidual interface and, consequently, 
leakage of phIGFBP-1 into the cervix.
Nulliparous women had signifi cantly higher rate of phIGFBP-1 concentrations ≥ 10μg/l 
in cervical fl uid than parous women in the fi rst and mid-second trimester. The reason for 
this remains unclear, and is in contrasts with the data of fetal fi bronectin (Goldenberg et 
al. 2000). It is of interest that the association with elevated phIGFBP-1 was strongest in 
nulliparous women with previous pregnancies, i.e miscarriage or termination of pregnancy. 
This suggests that women with previous miscarriage(s) may have reasons, still unknown 
to us, which increase phIGFBP-1 leakage from choriodecidual interface and may predict 
complications in ongoing pregnancy as well.
 
PhIGFBP-1 as a predictor of spontaneous PTD among asymptomatic women in the 
fi rst and mid-second trimester (II) 
The overall PTD rate at < 37 weeks of gestation in our study (4.4%) was lower than the 
national fi gure 5.2% in Finland (Jakobsson et al. 2008), and also lower compared with that 
at our university hospital area (5.5 %) during the same time period (THL, unpublished 
data). This indicates that our study population represented low risk women. 
Because spontaneous PTD is a long-standing process, dating back to the fi rst trimester, 
we examined whether elevated concentrations of phIGFBP-1 in cervical fl uid among 
asymptomatic women in early- or mid-pregnancy are associated with an increased risk of 
subsequent spontaneous PTD. 
Our data (II) demonstrate that women with subsequent PTD at < 32 weeks of gestation had 
signifi cantly higher cervical fl uid phIGFBP-l concentrations in both trimesters compared 
with women who delivered at ≥ 32 weeks of gestation. Secondly, our study showed that the 
frequencies of PTD among women with an elevated cervical fl uid phIGFBP-1 level either 
in the fi rst trimester or in the mid-second trimester were signifi cantly higher compared with 
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women with cervical phIGFBP-1 < 10 μg/l. The risk of PTD < 32 weeks of gestation was 
almost 4-fold-increased among women who had cervical phIGFBP-1 concentration ≥ 10 
μg/l compared with those with cervical phIGFBP-1 < 10 μg/l in the fi rst trimester. The risk 
of PTD among the women with cervical fl uid phIGFBP-1 ≥ 10 μg/l in the second trimester 
was almost 2-fold. 
After multivariate analysis including selected historical risk factors for PTD, an elevated 
cervical fl uid phIGFBP-1 in the fi rst trimester remained an independent predictor of PTD < 
32 weeks of gestation as well as < 37 weeks of gestation. Of the historical risk factors only 
previous PTD carried higher OR for PTD than elevated phIGFBP-1. This observation is in 
line with FFN. High values of FFN from 13 to 22 weeks of gestation have been shown to 
be associated with 2 to 3-fold increased risk of subsequent spontaneous PTD (Goldenberg 
et al. 2000). There are several explanations for our data. First, some women could have had 
subclinical intrauterine infection already before pregnancy or in early pregnancy, known 
to increase the risk of PTD, and an elevated cervical fl uid phIGFBP-1 refl ected infection-
induced tissue disruption at choriodecidual interface. This hypothesis is supported by 
Kekki’s study (1999), in which the women who had concurrently an asymptomatic BV 
and elevated phIGFBP-1 in cervical secretion in early second trimester had increased risk 
of peripartum infections (Kekki et al. 1999).  Considering the high frequency of elevated 
cervical fl uid phIGFBP-1 concentrations in our study population, this is probably not the 
only explanation. One reason for a higher rate of preterm deliveries among women with 
elevated cervical fl uid phIGFBP-1 in the fi rst trimester than in the second trimester could 
be the following: Before the fusion of capsular and parietal decidua there is an “open route” 
for the leakage of phIGFBP-1 from the decidua down to the cervix. Infections ascending 
from the vagina during that stage of pregnancy, indicated by the leakage of phIGFBP-1, 
may more often become chronic, resulting fi nally in PTD. This theory is in line with 
observations that the earlier in pregnancy the abnormal microbial intrauterine invasion has 
been detected the greater the risk for adverse outcome (Goldenberg et al. 2002, Iams 2003, 
Lamont and Sawant 2005, Redline 2004, Romero et al. 2006b).  
Yet, another explanation for an increased cervical fl uid phIGFBP-1 level as well as for an 
increased rate of PTD among women with elevated phIGFBP-1 could be past decidual 
haemorrhage. Decidual haemorrhage, appearing as vaginal bleeding is a well known 
etiologic factor of PTD (Goldenberg et al. 2008, Romero et al. 2006b). Although women 
with visible bleeding at the time of sampling were excluded, those with the history of 
vaginal bleeding were included. Among those an elevated cervical fl uid phIGFBP-1 could 
be a marker of previous (occult or clinical) decidual haemorrhage and associated tissue 
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disruption in decidua. Signifi cant association between previous vaginal bleeding and 
elevated cervical fl uid phIGFBP-1, as described in Study I and II supports this hypothesis. 
Previous vaginal bleeding in current pregnancy and elevated cervical fl uid phIGFBP-1 in 
the fi rst trimester also independently increased the risk for PTD. 
Elevated cervical fl uid phIGFBP-1 in the fi rst trimester was stronger predictor of PTD at < 
32 weeks of gestation than at < 37 weeks. This is an interesting observation considering that 
subclinical infection at choriodecidual interface, particularly in early pregnancy, has been 
associated especially with early PTD (Goldenberg et al. 2000, Iams 2003). According to 
the ROC curve analysis 10μg/l appeared to be optimal cut-off for cervical fl uid phIGFBP-1 
in predicting PTD < 32 weeks of gestation. The sensitivity (53.8%) of the fi rst trimester 
cervical fl uid phIGFBP-1 in the prediction of subsequent PTD < 32 weeks of gestation 
was strikingly high considering the multifactorial etiology and multiple pathophysiological 
pathways of PTD as well as timing of cervical fl uid sampling among asymptomatic women. 
In the mid-second trimester, the sensitivity of cervical phIGFBP-1 was lower. One reason 
for the low positive predictive values of phIGFBP-1 in both trimesters depends on the 
low rate of endpoints especially < 32 weeks of gestation. The negative predictive value 
of in this study was high, being in line with other studies among asymptomatic women at 
later stage of pregnancy (Altinkaya et al. 2009, Kekki et al. 2001, Paternoster et al. 2007). 
However, the high rate of false positive (physiologic) phIGFBP-1 values in early pregnancy 
limits the use of cervical phIGFBP-1 as a screening test for subsequent spontaneous PTD 
among asymptomatic women. Still, cervical fl uid phIGFBP-1 testing may be of value as an 
additional test in the assessment of preterm risk in selected cases also in early pregnancy. 
Of course, we need to consider that any testing adds little or nothing to outcome if we do 
not have right interventions to prevent spontaneous PTD (Honest et al. 2009). Thus, to 
develop new predictive and preventive methods more information is needed on physiology 
and pathophysiology of PTD in early pregnancy.
PhIGFBP-1 as a predictor of spontaneous PTD among symptomatic women (III) 
Preterm contractions are very subjective symptom but a cause of major anxiety for pregnant 
women and strain heltcare services. It is known that 30-40% of women with preterm 
contractions will end to PTD (Herbst and Nilsson 2006). In our study, 4.1% of women who 
presented unscheduled with self reported contractions between 22 and 34 weeks of gestation 
delivered < 34 weeks of gestation. This suggests that the study population represented 
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predominantly low-risk women. Secondly, this indicates that uterine contractions alone 
are poor predictor of PTD. Therefore, more sensitive and more specifi c tests to be used in 
combination with clinical judgment for identifying women who would benefi t of admission 
and preventive interventions are needed. Also unnecessary admissions and treatments 
should be avoided.  
In study III, we assessed the diagnostic performance of the rapid strip test for cervical fl uid 
phIGFBP-1 (actim partus test, Medix Biochemica) with the detection limit of 10 μg/l, and 
cervical length measurement as single tests and in combination with physician’s clinical 
judgment in the prediction of PTD ≤ 34 weeks of gestation in patients with self reported 
uterine contractions and intact membranes during the second half of pregnancy. Cervical 
length measurement was a part of clinical evaluation, whereas phIGFBP-1 test results were 
not available to the managing physician. 
The presence of phIGFBP-1 in cervical/vaginal fl uids during the second half of pregnancy 
is thought to be an indicator of infection/infl ammation associated tissue disruption at 
the choriodecidual interface (Rutanen 2000, Kekki et al. 2001). Also cervical ripening 
is associated with an increase in cervical fl uid phIGFBP-1 concentrations (Nuutila et al. 
1999). 
In our data (III) the rapid phIGFBP-1 test was positive in 14.6%. In a previous study by 
Kekki et al. (2001) about 5% of asymptomatic women and 27 % of women with preterm 
labor had phIGFBP-1 values ≥ 10μ/L in the lower genital tract in the late second and third 
trimester (Kekki et al. 2001). Similar results were reported by Eroglu et al 2007 (Eroglu 
et al. 2007). Two studies have reported three times higher rates of elevated phIGFBP-1 
concentrations in asymptomatic women between 24 to 34 weeks. In one of these studies 
women had a history of previous PTD (Bittar et al. 2007), whereas in another study women 
with a history of previous PTD were excluded (Altinkaya et al. 2009). In women with 
monitored regular contractions or PTL the reported rates of elevated phIGFBP-1 vary 
between 24-50 % (Altinkaya et al. 2009, Eroglu et al. 2007, Kekki et al. 2001, Kwek et al. 
2004, Lembet et al. 2002, Paternoster et al. 2009, Spinelli et al. 2009, Tanir et al. 2009, Ting 
et al. 2007). Thus, the low rate of positive phIGFBP-1 test results in our data in women with 
self-reported contractions also indicates that these women represented more low than high 
risk patients for PTD.
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The phIGFBP-1 test identifi ed 50% of patients who delivered ≤ 34 weeks, and 71.4% of 
those who had PTD within 14 days. The positive predictive values of the rapid phIGFBP-1 
test were lower in our study than in many other studies among symptomatic patients 
(Altinkaya et al. 2009, Akercan et al. 2004, Elizur et al. 2005, Eroglu et al. 2007, Kwek 
et al. 2004, Lembet et al. 2002, Paternoster et al. 2007, Paternoster et al. 2009, Ting et 
al. 2007), but in line with two studies among asymptomatic women (Altinkaya et al. 
2009, Paternoster et al. 2007), also supporting that our study population was mainly low 
risk. One reason accounting for the difference may be that patients in our study had self 
reported contractions, while in other studies patients have been in labour with monitored 
contractions. 
In our study short cervix (< 25 mm) was detected in 7.3% of women. Short cervix alone 
had lower sensitivity but higher positive predictive value than phIGFBP-1 alone, while 
clinician’s judgment (admission), including cervical length measurement predicted 7/10 
preterm deliveries < 34 weeks of gestation. This reveals the value of careful clinical 
assessment which includes sonographic cervical length measurement. Since a negative 
phIGFBP-1 test has a high negative predictive value for PTD, comparable to that of cervical 
length measurement in this and other studies (Eroglu et al. 2007, Paternoster et al. 2009), it 
may provide a valuable alternative to ultrasonographic cervical length measurement to be 
used in combination with clinical evaluation in prediction of PTD, especially if equipments 
or skills for ultrasonographic cervical length measurement are missing. 
Unfortunately, we did not have repeated tests from the study population so we do not 
know whether phIGFBP-1 persisted in some women or whether it was only associated 
with contractions. It is possible that increased uterine activity may cause tissue disruption 
or decidual bleeding in choriodecidual interface which subsequently heals and pregnancy 
continues uncomplicated. This was supported by an association between previous vaginal 
bleeding and a positive phIGFBP-1 test result. Further studies with sequential sampling are 
needed to clarify this issue. As informed by the manufacturer (Medix Biochemica), overt 
bleeding is a confounder for phIGFBP-1 bed-side testing since similar phosphoisoforms of 
IGFBP-1 predominate in decidua and maternal blood (Martina et al. 1997). 
In line with our study, previous studies with combinations of phIGFBP-1 rapid test and 
cervical length measurements, using the cutoff of 25mm, have lower sensitivity but higher 
specifi city suggesting better likelihoods ratios for PTD (Bittar et al. 2007, Eroglu et al. 
2007, Paternoster et al. 2009). Two studies have compared phIGFBP-1 and FFN bedside 
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tests for predicting PTD within 7 days. Both test showed to have equal effi ciency in patients 
with signs and symptoms of PTD (Eroglu et al. 2007, Ting et al. 2007). 
MMP-8 concentrations and factors affecting them in cervical and vaginal fl uids in 
the fi rst and mid-second trimester (IV,V)  
Matrix metalloproteinase 8 (MMP-8), a collagenase, is released from the secondary granules 
of polymorphonuclear cells in response to chemotactic stimulation during infl ammatory or 
infectious conditions. Furthermore, evidence is emerging that a wide range of infl ammatory, 
mesenchymal, epithelial and malignant cells can express MMP-8 (Hanemaaijer et al. 1997, 
Maymon et al. 2000c, Sorsa et al. 2006, Van Lint and Libert 2006). We report for the fi rst 
time the presence, concentrations, and factors associating with MMP-8 in the lower genital 
tract in fi rst and mid-second trimester. To our knowledge there is only one previous report 
on MMP-8 concentrations in vaginal fl uid (Diaz-Cueto et al. 2006). Increased MMP-8 
in cervical tissue with cervical ripening has been described in several studies (Dubicke 
et al. 2008, Sennstrom et al. 2003, Winkler et al. 1999). MMP-8 concentrations and their 
associations with infections and PTD have mainly been studied in AF (Biggio et al. 2005, 
Kim et al. 2007, Lee et al. 2008a, Maymon et al. 2000c, Maymon et al. 2001a, Maymon et 
al. 2001b, Nien et al. 2006, Park et al. 2008).   
In our study IV almost 100% of women had detectable MMP-8 concentrations in lower 
genital tract. The distribution of MMP-8 was markedly skewed in both trimesters, refl ecting 
that most pregnant women typically have low levels of this substance in the lower genital 
tract. The overall distribution was similar in early and mid second trimester. However, the 
median MMP-8 concentration was about three times higher in the cervix than in the vagina 
in both trimesters.
Possible explanations for the detected differences between vaginal and cervical MMP-8 
concentrations can be for example individual variations in the amount of vaginal or cervical 
fl uids as well as variations in the time the swab is allowed to absorb those fl uids. Elevation 
of MMP-8 concentrations in the cervical canal also indicates enhanced neutrophil activation 
and may eventually refl ect the variety of pathophysiologic pathways that are involved in 
ascending infection into the decidua. Other cellular origins and biological functions for 
MMP-8 are also possible. However, these variables do not account for the wide range of 
MMP-8 values in our study. In a previous study, MMP-8 concentration was consistently 
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higher in amniotic fl uid obtained from the lower uterine compartment than in the fl uid from 
the upper compartment, suggesting that MMP-8 may act locally and play a role in tissue 
remodelling before rupture of the membranes (Maymon et al. 2000c). This and our present 
fi ndings suggest that MMP-8 in the lower uterine compartment and in cervical canal is 
involved in the physiologic infl ammation process during pregnancy. 
In agreement with reports on MMP-8 in amniotic fl uid and fetal membranes, MMP-8 
concentrations in cervical fl uid were highly variable (Biggio et al. 2005, Lee et al. 2007, 
Maymon et al. 2000). This and the only moderate correlation between the fi rst trimester and 
second trimester MMP-8 values, as shown in our study, suggest that factors or events that 
regulate local MMP-8 concentrations in the cervical fl uid, such as neutrophil degranulation 
induced by proinfl amatory mediators or microbial factors, are inconstant at least in early 
and mid-pregnancy.
In our study IV and V, MMP-8 concentrations in cervical fl uids were 10-100 times higher 
than those reported in amniotic fl uid without microbial invasion, but similar to those in 
amniotic fl uid with microbial invasion (Biggio et al. 2005, Lee et al. 2007, Maymon et al. 
2000). 
BV, with incidence only of 4 % in our study IV, was associated with increased MMP-
8 concentrations in the cervical and vaginal samples. In previous studies BV has been 
reported in 15 % - 30 % of non-pregnant women, and in up to 50 % of pregnant women 
(Goldenberg et al. 1996, Goldenberg et al. 1998, McGregor and French 2000, Meis et al. 
1995, Nelson et al. 2009). In another study with BV incidence of 47 %, BV was associated 
with increased MMP-8 concentration in vagina (Diaz-Cueto et al. 2006). In two previous 
Finnish studies among nulliparous women, the BV incidence has been 10% to 21%, 
indicating some biologic fl uctuation in Finnish population over time in the incidence of 
BV (Kekki et al. 1999, Kekki et al. 2001, Kurki et al. 1992). The same diagnostic criteria 
of BV were used as in our study. According the previous studies BV increases the risk for 
spontaneous PTD and PPROM 2- to 3-fold (Goldenberg et al. 2000, Romero et al. 2004). 
Thus, low incidence of BV may partly explain the low incidence of PTD (4%) in our study. 
One third of women (IV) had elevated amount of leukocytes, quantifi ed from vaginal 
smears, with signifi cant association with increased MMP-8 concentrations in lower genital 
tract in both trimesters. This association was strongest in the women with increased vaginal 
leukocytes together with BV. Elevated amount of leukocytes may be a marker of vaginal 
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infection or infl ammation and may refl ect the host defence mechanisms, while BV alone 
is not associated with signs of infl ammation despite substantial microbial overgrowth 
(Goldenberg et al. 2000, Hay et al. 1994, Romero et al. 2004). The most likely explanation 
for elevated MMP-8 concentration is the recruitment and activation of neutrophils by micro-
organisms in the vagina and cervical canal which may further ascend into the choriodecidual 
space. This hypothesis is supported by an in vitro study, where the incubation of membranes 
with microbial proteases reduced their strength and elasticity (McGregor et al. 1986). In 
addition, an elevated MMP-8 level cervicovaginal fl uid could be also a potential marker for 
infection in the lower genital tract and, therefore, an indicator of an increased risk of PTD. 
However, it is not clear whether MMP-8 acts only locally.
MMP-8 has been described to correlate with cervical ripening (Dubicke et al. 2008, 
Sennstrom et al. 2003). In our study IV and V, cervical and vaginal fl uid MMP-8 
concentrations were three times higher in multiparous than in nulliparous women in the 
fi rst and the second trimester. This suggests that the cervical connective tissue, mainly 
type I collagen, is more exposed to proteolytic modulation due to the previous deliveries. 
In a murine model the enhanced proteolytic burden involving MMP-8 in post partum 
cervical involution, associated with earlier deliveries, can eventually modify the cervical 
connective tissue by revealing cryptic (extracellular matrix) neoepitopic fragments in 
extracellular matrix, possessing thus chemotactic activities for neutrohilic leukocytes (Van 
Lint and Libert 2006, Uldbjerg et al. 1983a). Consequently, the triggered neutrophils may 
degranulate their MMP-8, or alternatively, neutrophil-derived proinfl ammatory mediators 
may induce de-novo expression of MMP-8 by resident cervical non-neutrophil-lineage cells 
(fi broblasts, epithelial cells etc). In this regard the cervical connective tissue compartment of 
multiparous women eventually differs from nulliparous women whose cervical connective 
tissue has not experienced the delivery-associated enhanced proteolytic burden. Another 
explanation may be that the volume and quality of cervical mucus plug differ between 
multiparous and nulliparous women. This smear separates uterine cavity from potentially 
harmful bacteria colonizing the vagina. The neutrophils are expected to invade the plug 
from the surrounding endocervix, a permanent site for infl ammation during pregnancy. 
The plug is bactericidal and contains large amounts of antimicrobial factors, including 
secretory leukoprotease inhibitors, suggesting local defence mechanism, a physical but also 
a biochemical barrier which protects the fetomaternal unit against ascending intrauterine 
infection during pregnancy (Hein et al. 2001). 
In addition to it’s classical tissue destructive activity, MMP-8 can also process and 
activate anti-infl ammatory cytokines, chemokines and defensins involved in the defensive 
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processes, and thus exert protective action against infection induced infl ammations (Balbin 
et al. 1998, Gueders et al. 2005, Kuula et al. 2009, Owen et al. 2004, Sorsa et al. 2006, Van 
Lint and Libert 2006). Therefore, elevated MMP-8 in vagina and in cervix of multiparous 
relative to the nulliparous women may refl ect, at least in part, host protection against 
infections and BV.
In our studies IV and V previous vaginal bleeding during pregnancy had no effect on 
vaginal and cervical MMP-8 concentrations, suggesting that MMP-8 level in vaginal or 
cervical secretion does not reveal the reason of vaginal bleeding. 
In our study IV and study V, one third to one forth women expressed having had sexual 
intercourse during the last 48 hours before sampling. Both our data showed that sexual 
intercourse was associated with decreased MMP-8 concentration in the lower genital in 
both trimesters. This fi nding is of a great interest but diffi cult to explain, since no reports 
have been published on the relationship between MMP-8 and seminal plasma in female 
genital tract. Our results suggest that seminal plasma may decrease MMP-8 release from 
leukocytes, or seminal plasma may contain factors which can consume MMP-8. 
In study V remarkable overweight (BMI > 30 kg/m²) was associated higher MMP-8 
concentrations, which may refl ect persistent infl ammatory process in obese women. In 
previous studies, obesity has been associated with an increased risk of PPROM (Nohr et al. 
2007, Rosenberg et al. 2005), but this association was not found in our study. 
MMP-8 as a predictor of spontaneous PTD among asymptomatic women in the fi rst 
and mid-second trimester (V)
In our study V when all preterm deliveries were analysed as a group and compared with 
term deliveries, no difference was found in the median cervical fl uid MMP-8 concentrations 
either in the fi rst or mid-second trimester. However, low MMP-8 concentrations in the 
cervical fl uid were associated with PTD initiated by PPROM. Our data suggests that 
distinct molecular pathways may result in PTD initiated by PPROM and PTL. 
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The increase of MMP-8 concentrations in cervical canal eventually may refl ect enhanced 
neutrophil activation and maternal infl ammatory response to micro-organisms ascending 
from the vagina. Other cellular origins and biological functions for cervical MMP-8 are 
also possible. It is well known that the cervix becomes softer in pregnancy due to increased 
vascularity and a loosening of the connective tissue. This process, beginning weeks before 
delivery, involves intensive remodelling of the extracellular matrix with extensive changes 
in concentration and composition of collagens and other matrix components. The changes 
increase as pregnancy advances and peak as the cervix effaces and dilates during delivery 
(Bergelin and Valentin 2002, Iams 2003, Leppert 1995, Rath et al. 1998, Weiss et al. 2007). 
Considering its specifi c collagenolytic activity, MMP-8 may play an important role in this 
process. In keeping with this theory, MMP-8 is increased in cervical tissue during cervical 
ripening at term as compared with cervical tissue of non-pregnant women (Sennstrom et 
al. 2003). In our study V, high cervical fl uid MMP-8 concentrations in some of the women 
ending to PTD with intact membranes may refl ect increased collagenolytic activity in the 
cervix due to MMP-8.
It has been thought that neutrophils and MMP-8 in amniotic fl uid represent fetal infl ammatory 
response to infections ascending from the vagina into choriodecidual space (Goldenberg 
et al. 2008, Mercer 2003, Iams 2003, Nien et al. 2006, Romero et al. 2006b). Microbial 
invasion of the amniotic cavity has been associated with a signifi cant increase in amniotic 
fl uid MMP-8 concentrations in patients with PTL and intact membranes as well as in patients 
with PPROM (Maymon et al. 2000). The association between low cervical fl uid MMP-8 
concentrations and subsequent PPROM, as seen in our study V, differs from the amniotic 
fl uid fi ndings by Biggio et al (2005). They demonstrated that the overall distribution of 
mid-trimester amniotic fl uid MMP-8 concentrations did not differ between women with 
term and subsequent PTD, but marked elevation (> the 90 percentile) of MMP-8 was 
highly associated with subsequent PPROM (Biggio et al. 2005). These fi ndings suggest 
that distinct functions of MMP-8 are involved in amniotic fl uid and in cervical fl uid in 
cases with PPROM during pregnancy. In addition, Lee at al (2008) recently demonstrated 
that intraamniotic infl ammation, regardless of amniotic fl uid culture result, is present in 
approximately 80% of patients with acute cervical insuffi ciency (Lee et al. 2008a). It is 
thought that the detection of infl ammation in amniotic fl uid may be more practical than 
the detection of infection in patient management (Shim et al. 2004). Furthermore, recent 
evidence has demonstrated that patients with intraamniotic infl ammation but a negative 
microbiologic culture have a similar adverse pregnancy outcome than those with positive 
culture, which may refl ect the fetal infl ammatory response (Maymon et al. 2001b, Shim et 
al. 2004, Yoon et al. 2001). Still, the source of neutrophils in amniotic fl uid and cervical fl uid 
may differ. Further studies are needed to clarify reason(s) for this diversity in cervical fl uid 
MMP-8 (maternal response) and amniotic fl uid MMP-8 (fetal response) concentrations in 
relation to PPROM.
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Recent genetic epidemiological PTD studies suggest that certain women are hyperresponders 
and some hyporesponders to microorganisms (Romero et al. 2004, Simhan et al. 2003). 
In support of this hypothesis Simham et al recently reported that women with lower 
concentrations of cytokines in the vaginal fl uid in early pregnancy more likely develop 
clinical chorionamnionitis than those without low concentration of these cytokines (Simhan 
et al. 2003). Hyporesponding patient with low concentration of cytokines, and consequently 
possibly MMP-8, then would be predisposed to overgrowth of microorganisms and 
ascending intrauterine infection (Romero et al. 2004). This suggestion is further supported 
and extended by our fi ndings revealing decreased cervical fl uid MMP-8 concentrations in 
mid pregnancy in some women with subsequent PPROM. Low level of MMP-8 in cervical 
fl uid refl ects reduced release of MMP-8 from neutrophils in the lower genital tract. This 
might refl ect an impaired defensive immunoresponse to microbial invasion into the decidua 
and membranes in certain women. In this regard, MMP-8 seems to induce a protective 
and anti-infammatory action against infection as demonstrated by MMP-8 knock out mice 
studies (Gueders et al. 2005, Kuula et al. 2009). Indeed, low MMP-8 concentrations are 
associated with delayed or impaired neutrophil function (Van Lint and Libert 2006). 
Altogether data of recent MMP-8 studies suggest dual roles in the lower genital tract, 
destructive and defensive. The clinical signifi cance of these observations regarding PTD 
remains to be clarify. 
Strengths and limitations of the studies
The strength of this study is that it gives us baseline knowledge of phIGFBP-1 and MMP-
8 with large size of sample. Another, strength was it was population based with a low 
drop out rate. All phIGFBP-1 and MMP-8 measurements were performed each in a single 
laboratory and in study IV the vaginal smear slides were processed and examined by one 
laboratory technician without the knowledge of any clinical characteristics of the study 
subjects. In study II and V the rate of preterm deliveries in our study was comparable to 
that in general population. In addition, known risk factors and their contributions for the 
risk of PTD were considered. 
One of the limitation is that vaginal bacterial fl ora was analyzed only in study III and IV. 
Furthermore we did not test specifi c vaginal infections, such as Clamydia trachomatis, 
Trichomoniasis, Mycoplasma or group B β- streptococcus, considering that vaginal 
infections with neutrophil activation may play a crucial role in cervical canal and 
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choriodecidual space. Unfortunately in study III, we had not repeated tests from the study 
population so we do not know whether phIGFBP-1 persisted in some women or whether 
it was only associated with contractions. And we did not have FFN test at the same time 
for comparison with phIGFBP-1 test performances. In addition, in study V we analyzed 
only one matrix metalloproteinase, MMP-8, although other metalloproteinases and their 
regulators are likely to play a role in pregnancy and some of them evidently also contribute 
to the infl ammatory mileu of the lower genital tract. Furthermore, we unfortunately 
did not have the results of leukocytes in vaginal smear and BV together with MMP-8 
concentrations for prediction to PTD in study V. In the future, further studies for diversity 
in cervical fl uid MMP-8 with bacterial vaginosis and specifi c infections in cases of PPROM 
and spontaneous labour are required to draw conclusions.
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CONCLUSIONS 
The following conclusions can be drawn:
• PhIGFBP-1 and MMP-8 are present in lower genital tract fl uids in the fi rst and mid-second 
trimester. Both phIGFBP-1 and MMP-8 concentrations were higher in cervical fl uid than in 
vaginal fl uid. These data indicate that the site of sampling is important when these biomarkers 
are measured in the lower genital tract.  
• The levels and the occurrence of cervical fl uid phIGFBP-1 concentrations of ≥ 10 μg/l 
decreased signifi cantly from the fi rst to the second trimester. Nulliparity, especially in women 
with previous pregnancies and previous vaginal bleeding in the current pregnancy, was were 
associated with phIGFBP-1 values of ≥ 10 μg/l in cervical fl uid samples.
• An elevated concentration (≥ 10 μg/l) of cervical fl uid phIGFBP-1 in the fi rst trimester was an 
independent predictor of PTD (OR 3.0) with a high NPV for PTD among asymptomatic women 
in early and mid-pregnancy. Because of its relatively low sensitivity and specifi city, assay of 
cervical fl uid phIGFBP-1 is not appropriate for screening for PTD risk in early pregnancy, but 
it may provide an additional tool when assessing the risk of PTD in selected cases in early 
pregnancy.
• In women with self-reported uterine contractions between 22 and 34 weeks of gestation, 
a positive rapid phIGFBP-1 bedside test result was associated with a 7-fold increased risk 
of PTD, and a negative test result had a negative predictive value comparable to that of 
ultrasonographic cervical length measurement. Thus, the rapid phIGFBP-1 strip test may 
provide a valuable alternative or addition to ultrasonographic cervical length measurement to 
be used in combination with clinical assessment in prediction of PTD in symptomatic women 
presenting with contractions. 
• MMP-8 was present in the lower genital tract in almost 100% of the women, at concentrations 
ranging from 0.08 to 2000 μg/l. No difference was found in the values between the fi rst and 
second trimester. Bacterial vaginosis, vaginal leukocytosis, multiparity and an overweight 
condition are signifi cantly associated with increased levels of MMP-8 in cervical fl uids.
• Cervical fl uid MMP-8 concentrations in early and mid-pregnancy are not related to subsequent 
PTD. However, low concentrations of cervical fl uid MMP-8 were associated with PTD initiated 
by PPROM. These data suggest that the molecular mechanisms and pathophysiological 
pathways resulting in PTD after PTL and after PPROM differ, and MMP-8 concentrations in the 
low and upper ranges possibly refl ect dual roles of MMP-8, i.e. destructive and defensive. The 
clinical signifi cance of these fi ndings in relation to obstetric outcomes remains to be studied. 
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